Condensed thiophene derivatives as hypoxia-inducible factor (HIF) inhibitors
By developing thiophene derivative compounds, the shortcomings of existing HIF-2α inhibitors have been addressed, providing a treatment option with high activity and good tolerability for HIF-2α, especially for cancers such as clear cell renal cell carcinoma, achieving significant cell reduction effects.
Patent Information
- Application Number
- CN202080082153.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-26
- Filing Date
- 2020-11-24
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-11-24
AI Technical Summary
There is a lack of effective HIF-2α inhibitors in the current technology, especially in the treatment of cancers such as clear cell renal cell carcinoma (ccRCC). Dysregulation of HIF-2α is associated with poor patient prognosis, and the pharmacological properties and tolerability of existing inhibitors need to be improved.
A new class of thiophene derivative compounds has been developed that, through specific structural modifications, can efficiently inhibit HIF-2α. These compounds include compounds of formula I and their pharmaceutically acceptable salts, solvates, tautomers, and stereoisomers, for use in preparing pharmaceutical compositions for the treatment of related diseases.
These compounds exhibit high activity against HIF-2α, good pharmacological properties and tolerability, and can significantly reduce the target cell population, providing an effective treatment option, especially for HIF-2α dysregulated cancers such as ccRCC.
Smart Images

Figure CN114829349B_ABST
Abstract
Description
Background of the Invention
[0002] The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.
[0003] The present invention relates to thiophene derivatives that inhibit HIF-2α (Hypoxia-Inducible Factor). The compounds of the present invention are therefore useful in treating diseases such as cancer.
[0004] The present invention also provides methods for preparing these compounds, pharmaceutical compositions containing these compounds, and methods for treating diseases using pharmaceutical compositions containing these compounds.
[0005] Providing adequate oxygen to tissues is essential for maintaining mammalian cell function and physiology. Insufficient tissue oxygen supply is a characteristic of many pathophysiological conditions in which blood flow is insufficient to provide adequate oxygenation, such as ischemic disorders, cancer, and atherosclerosis. The hypoxic (low oxygen) environment of tissues activates signaling cascades that drive the induction or inhibition of transcription of many genes associated with events such as angiogenesis (neovascularization), glucose metabolism, and cell survival / death. The key to this hypoxic transcriptional response is the transcription factor, hypoxia-inducible factor (HIF).
[0006] HIF is dysregulated in a large number of cancers through hypoxia-dependent and -independent mechanisms, and expression is associated with poor patient prognosis. Hypoxia-inducible factors (HIFs), including HIF-1α and HIF-2α, are transcription factors that mediate the cellular response to reduced oxygen supply. These proteins become stabilized under hypoxia (low oxygen) and subsequently activate gene expression to promote cell survival and proliferation. HIF proteins are activated in many types of cancer and are associated with cancer initiation, progression, and metastasis. The role of HIF-2α is particularly important in clear cell renal cell carcinoma (ccRCC). In most ccRCC tumors, the tumor suppressor von Hippel-Lindau protein (pVHL), which targets HIF-2α for degradation, is inactivated, leading to the accumulation of HIF-2α and the transcription of genes that drive renal cancer tumorigenesis. Certain cancers, including renal cell carcinoma, display high levels of HIF-2α and dependence on HIF-2α signaling.
[0007] HIF-2α protein has been detected in various human tumors of the bladder, breast, colon, liver, ovary, pancreas, prostate, and kidney, as well as in tumor-associated macrophages.
[0008] The compounds of the present invention show high activity against HIF-2α in a variety of relevant settings including biochemical, biophysical and cellular assays.
[0009] It has been found that the compounds according to the invention and their salts possess very valuable pharmacological properties while being well tolerated.
[0010] The host or patient may be of any mammalian species, such as primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are attractive for experimental studies and provide models for treating human diseases.
[0011] The susceptibility of specific cells to treatment with compounds according to the present invention can be determined by in vitro testing. Generally, cell culture is combined with compounds according to the present invention at various concentrations for a period of time, which is enough to enable an activating agent such as anti-IgM to induce cell responses such as the expression of surface markers, usually between about one hour to one week. Cultured cells from blood or biopsy specimens can be used to carry out in vitro testing. The amount of the surface markers expressed is evaluated by flow cytometry using the specific antibodies of the recognition markers.
[0012] The dosage varies depending on the specific compound used, the specific disease, the patient's condition, etc. The therapeutic dose is generally sufficient to significantly reduce the unwanted cell population in the target tissue while maintaining the patient's vitality. Treatment is usually continued until a significant reduction in the cell burden occurs, such as a reduction of at least about 50%, and can be continued until substantially no unwanted cells are detected in the body. Prior art
[0013] Other HIF-2α inhibitors for treating cancer are described in WO 2018 / 031680 A1, WO 2015 / 035223 A1, WO 2016 / 145045 A1, WO 2016 / 145032 A1, WO 2016 / 144825 A1, WO 2016 / 144826 A1 and WO 2016 / 168510 A1.
[0014] H. Cho et al. Nature, Vol. 539, 2016, 107-122 (doi: 10.1038 / nature19795) and W. Chen et al. Nature, Vol. 539, 2016, 112-130 (doi: 10.1038 / nature19796) describe preclinical targeted efficacy studies of HIF-2α antagonists.
[0015] A review of the pathways targeted by FIIF-2a is described in SE Wilkins Chem Med Chem, 2016, 11, 773-786. Summary of the invention
[0016] The present invention relates to compounds of formula I:
[0017]
[0018] in
[0019] R 1 Indicates A, [C(R 6 )2] q Ar, [C(R 6 )2] q Cyc, [C(R 6 )2] q Het or COA,
[0020] R 2 Represents SO2A, SOA, SA, SO2NHA, SO2NA2, S(=NH,=O)A, S(=NH)2A, NO2, Hal, CN, A, Het 1 , COOH or COOA,
[0021] R 3 Indicates H or Hal,
[0022] R 4 Indicates H or Hal,
[0023] R 5 Indicates H or Hal,
[0024] R 6 Indicates H or A',
[0025] A represents an unbranched or branched alkyl radical having 1 to 8 C atoms, of which 1 to 5 H atoms may be replaced by OH, OA, F, Cl and / or Br and / or one or two non-adjacent CH2 groups may be replaced by O and / or NH groups, A' represents an unbranched or branched alkyl radical having 1, 2, 3 or 4 C atoms,
[0026] Cyc represents a cyclic alkyl radical having 3, 4, 5, 6 or 7 C atoms, of which 1 to 5 H atoms may be replaced by OH, OA, F and / or Cl,
[0027] Ar represents phenyl, which is unsubstituted or substituted by Hal, A, NH2, NHA, NA2, COOH, COOA, CONH2, CONHA, CONA2, CONHAr, S(O) p A, NHCH2Ar, CN, OH and / or OA are mono-, di- or trisubstituted,
[0028] Het represents a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O and / or S atoms, which may be unsubstituted or substituted by Hal, A, NH2, NHA, NA2, COOH, COOA, CONH2, CONHA, CONA2, CONHAr, S(O) p A, NHCH2Ar, CN, OH and / or OA are mono-, di- or trisubstituted,
[0029] Het 1 represents a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, COOA, NH2, NHA and / or NA2,
[0030] Hal represents F, Cl, Br or I,
[0031] n represents 1 or 2,
[0032] m represents 0, 1, 2 or 3,
[0033] p means 1, 2 or 3,
[0034] q represents 0, 1 or 2,
[0035] and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
[0036] The invention also relates to the optically active forms (stereoisomers), enantiomers, racemates, diastereomers and hydrates and solvates of these compounds.
[0037] Furthermore, the present invention relates to pharmaceutically acceptable derivatives of the compounds of formula I.
[0038] The term solvates of the compounds is used to describe the addition of inert solvent molecules to the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.
[0039] It will be understood that the present invention also relates to the solvates of the salts.
[0040] The term pharmaceutically acceptable derivatives is taken to mean, for example, the salts of the compounds according to the invention and also so-called prodrug compounds.
[0041] As used herein and unless otherwise indicated, the term "prodrug" means a derivative of a compound of formula I that can be hydrolyzed, oxidized or otherwise reacted under biological conditions (in vitro or in vivo) to provide an active compound, particularly a compound of formula I. Examples of prodrugs include, but are not limited to, derivatives and metabolites of compounds of formula I containing the following biohydrolyzable moieties: such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides and biohydrolyzable phosphate analogs. In certain embodiments, the prodrug of a compound with a carboxyl functional group is a lower alkyl ester of a carboxylic acid. Carboxylic acid esters are conveniently formed by esterifying any carboxylic acid moieties present on the molecule. Prodrugs can generally be prepared using well-known methods, such as those described by Burger's Medicinal Chemistry and Drug Discovery 6th edition (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).
[0042] The expression "effective amount" denotes that amount of a drug or a pharmaceutically active ingredient that elicits in a tissue, system, animal or human the biological or medical response that is sought or desired, for example, by a researcher or physician.
[0043] In addition, the expression "therapeutically effective amount" refers to an amount that has the following results compared to a corresponding subject not receiving the amount:
[0044] Improved treatment, cure, prevention or elimination of a disease, syndrome, condition, ailment, disorder or side effect, or also reduced progression of a disease, ailment or disorder.
[0045] The expression "therapeutically effective amount" also encompasses amounts effective for increasing normal physiological function.
[0046] The invention also relates to the use of mixtures of compounds of formula I, such as a mixture of two diastereoisomers, for example in a ratio of 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.
[0047] These are particularly preferably mixtures of stereoisomeric compounds.
[0048] "Tautomers" refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment in which the compound is found, and may vary depending on, for example, whether the compound is a solid or in an organic or aqueous solution.
[0049] The present invention relates to compounds of formula I and salts thereof and methods for preparing compounds of formula I and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterized in that
[0050] a) reacting the compound of formula II with NaBH4 or any other reducing agent
[0051]
[0052] Where R 1 , R 2 , R 3 , R 4 , R 5 , m and n have the meanings indicated in Formula I above and in the present disclosure, and / or
[0053] The base or acid of formula I is converted into one of its salts.
[0054] In this context, the group R 1 , R 2 , R 3 , R 4 , R 5 , m and n have the meanings indicated for formula I, unless expressly stated otherwise.
[0055] A is alkyl, which is unbranched (linear) or branched and has 1, 2, 3, 4, 5, 6, 7 or 8 C atoms. A preferably is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably for example trifluoromethyl.
[0056] A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl.
[0057] Furthermore, A preferably represents CH2OCH3, CH2CH2OH or CH2CH2OCH3.
[0058] Furthermore, A preferably denotes an unbranched or branched alkyl radical having 1 to 6 C atoms, wherein 1 to 5 H atoms may be replaced by OH and / or F and / or one or two non-adjacent CH2 groups may be replaced by O and / or NH groups.
[0059] A′ preferably denotes alkyl having 1, 2, 3 or 4 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.
[0060] R 1 Preferably represents A, [C(R 6 )2] q Ar, [C(R 6 )2] q Cyc or [C(R 6 )2] q Het.
[0061] R 2 Preferably it represents SO2A, most preferably SO2CH3.
[0062] R 3 Preferably it represents H or F.
[0063] R 4 Preferably it represents H or F.
[0064] R 5 Preferably it represents H.
[0065] Cyc preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, in which 1 to 5 H atoms may be replaced by OH, OA, F and / or Cl.
[0066] Without taking into account further substitutions, Het represents, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, more preferably 1,2,3-triazolyl-1-, -4- or -5-yl, 1,2 , 4-triazolyl-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazole 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzoisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzoisothiazolyl, 4-, 5-, 6- or 7-benzo-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopyridinyl, purinyl, further preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxane-6-yl, 2,1,3-benzothiadiazole-4- or -5-yl, 2,1,3-benzoxadiazole-5-yl, azabicyclo[3.2.1]-octyl or dibenzofuranyl.
[0067] The heterocyclic radicals may also be partially or fully hydrogenated.
[0068] Without taking into account further substitutions, Het can therefore also represent, for example, 2,3-dihydro-2-, -3-, -4- or -5-furanyl, 2,5-dihydro-2-, -3-, -4- or 5-furanyl, tetrahydro-2- or -3-furanyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2-, 3-, 4- or 5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, phenyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo-1,4-oxazinyl, further preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylene) 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-dihydro-2H-1,5-benzodioxin-6- or -7-yl, further preferably 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2-oxo-1H-quinazolinyl, 2,3-dihydrobenzoxazolyl, 2-oxo-2,3-dihydrobenzoxazolyl, 2,3-dihydrobenzimidazolyl, 1,3-dihydroindole, 2-oxo-1,3-dihydroindole or 2-oxo-2,3-dihydrobenzimidazolyl.
[0069] Without considering further substitution, Het 1represents, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, and more preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -4- or -5-yl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4-, or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6-, or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4-, or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6-, or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4-, or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6-, or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4-, or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6-, or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4-, or 5-benzimidazolyl, 1-, 3-, 4- 1-, 3-, 4-, 5-, 6-, or 7-benzopyrazolyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 3-, 4-, 5-, 6-, or 7-benzoisoxazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl, 2-, 4-, 5-, 6-, or 7-benzoisothiazolyl, 4-, 5-, 6-, or 7-benzo-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl, 3-, 4-, 5-, 6-, or 7-benzothiazolyl, 2-, 4-, 5-, 6-, or 7-benzoisothiazolyl, , 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopyridinyl, purinyl, further preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxane-6-yl, 2,1,3-benzothiadiazole-4- or -5-yl, 2,1,3-benzoxadiazole-5-yl, azabicyclo[3.2.1]-octyl or dibenzofuranyl.
[0070] The heterocyclic radicals may also be partially or fully hydrogenated.
[0071] Without considering further substitution, Het 1It may also represent, for example, 2,3-dihydro-2-, -3-, -4- or -5-furanyl, 2,5-dihydro-2-, -3-, -4- or 5-furanyl, tetrahydro-2- or -3-furanyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2-, 3- or 4-pyranyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo-1,4-oxazinyl, further preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)benzene phenyl or 3,4-dihydro-2H-1,5-benzodioxin-6- or -7-yl, further preferably 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2-oxo-1H-quinazolinyl, 2,3-dihydrobenzoxazolyl, 2-oxo-2,3-dihydrobenzoxazolyl, 2,3-dihydrobenzimidazolyl, 1,3-dihydroindole, 2-oxo-1,3-dihydroindole or 2-oxo-2,3-dihydrobenzimidazolyl.
[0072] Het preferably denotes a monocyclic saturated heterocycle having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, OH and / or OA.
[0073] Het particularly preferably denotes tetrahydrofuranyl, 1,3-dioxolanyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl or piperazinyl.
[0074] Ar represents, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methylaminocarbonyl)phenyl, o-, m- or p-acetylaminophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-(N,N Preferably, the phenyl group is selected from the group consisting of: phenyl, o-, m- or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N,N-diethylamino)phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-(methylsulfonylamino)phenyl, o-, m- or p-(methylsulfonyl)phenyl, o-, m- or p-cyanophenyl, o-, m- or p-carboxyphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p-(benzylamino)phenyl, and more preferably The first group is 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylamino- phenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetylaminophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetylaminophenyl or 2,5-dimethyl-4-chlorophenyl.
[0075] Ar particularly preferably represents phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and / or CN.
[0076] Particularly preferred compounds of formula I are:
[0077]
[0078] Throughout the invention, all radicals which occur more than once may be identical or different, ie are independent of one another.
[0079] The compounds of formula I may have one or more chiral centers and may therefore exist in various stereoisomeric forms. Formula I encompasses all these forms.
[0080] The present invention therefore relates in particular to compounds of the formula I in which at least one of the radicals has one of the preferred meanings given above. Some preferred groups of compounds can be represented by the following sub-formulae Ia-Ih, which conform to the formula I and in which the radicals not specified in more detail have the meanings indicated for the formula I, but in which
[0081] In Ia, R 1 Indicates A, [C(R 6 )2] q Ar, [C(R 6 )2] q Cyc or [C(R 6 )2] q Het;
[0082] In Ib, R 2 It means SO2A;
[0083] In Ic, R 3 Indicates H or F,
[0084] R 4 Indicates H or F;
[0085] In Id, A represents A preferably represents an unbranched or branched alkyl group having 1 to 6 C atoms, wherein 1 to 5 H atoms may be replaced by OH and / or F, and / or one or two non-adjacent CH2 groups may be replaced by O and / or NH groups; in Ie, Ar represents phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal and / or CN;
[0086] In If, Het represents a monocyclic saturated heterocycle having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CN, OH and / or OA;
[0087] In Ig, Het represents tetrahydrofuranyl, 1,3-dioxolanyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl or piperazinyl;
[0088] In Ih, R 1 Indicates A, [C(R 6)2] q Ar, [C(R 6 )2] q Cyc or [C(R 6 )2] q Het;
[0089] R 2 Represents SO2A,
[0090] R 3 Indicates H or F,
[0091] R 4 Indicates H or F,
[0092] R 5 Indicates H,
[0093] R 6 Indicates H or A',
[0094] A represents an unbranched or branched alkyl radical having 1 to 8 C atoms, of which 1 to 5 H atoms may be replaced by OH and / or F and / or one or two non-adjacent CH2 groups may be replaced by O and / or NH groups,
[0095] A' represents an unbranched or branched alkyl group having 1, 2, 3 or 4 C atoms,
[0096] Cyc represents a cyclic alkyl radical having 3, 4, 5, 6 or 7 C atoms, of which 1 to 5 H atoms may be replaced by OH, OA, F and / or Cl,
[0097] Ar represents phenyl, which is unsubstituted or mono-, di- or tri-substituted by Hal and / or CN,
[0098] Het represents tetrahydrofuranyl, 1,3-dioxolanyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl or piperazinyl,
[0099] Hal represents F, Cl, Br or I,
[0100] n represents 1 or 2,
[0101] m represents 0, 1, 2 or 3,
[0102] p means 1, 2 or 3,
[0103] q represents 0, 1 or 2, and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
[0104] In addition, compounds of formula I and starting materials for their preparation are prepared by methods known per se as described in the literature (e.g. in standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), specifically under reaction conditions known and suitable for the reaction. Variants known per se that are not mentioned in greater detail here may also be used here.
[0105] The compound of formula I can preferably be obtained by reacting the compound of formula II with a complex hydride such as NaBH4 in an inert solvent such as MeOH or THF. The reaction is usually carried out at a temperature between 0°C and 75°C, preferably between 10°C and 40°C.
[0106] Medicinal salts and other forms
[0107] The compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also covers the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Most of the pharmaceutically acceptable salt forms of the compounds of formula I are prepared by conventional methods. If the compound of formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to obtain the corresponding base addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, such as potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. Aluminum salts of the compounds of formula I are also included. In the case of certain compounds of Formula I, acid addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, such as hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts, such as sulfates, nitrates or phosphates, and the like, as well as alkyl and monoaryl sulfonates, such as ethanesulfonates, toluenesulfonates and benzenesulfonates, and other organic acids and their corresponding salts, such as acetates, trifluoroacetates, tartrates, maleates, succinates, citrates, benzoates, salicylates, ascorbates, and the like. Thus, pharmaceutically acceptable acid addition salts of compounds of Formula I include the following: acetate, adipate, alginate, argininate, aspartate, benzoate, besylate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, octanoate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, fumarate, formate, galactarate (from mucic acid), galacturonate, glucoheptonate, gluconate, glutamate. , glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a limitation.
[0108] In addition, alkali salts of the compounds according to the invention include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium, magnesium, manganese (III), manganese (II), potassium, sodium and zinc salts, but this is not intended to represent a limitation. Among the above salts, ammonium salts; alkali metal salts sodium and potassium salts, and alkaline earth metal salts calcium and magnesium salts are preferred. Salts of compounds of formula I derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines (also including naturally occurring substituted amines), cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, TEA, trimethylamine, tripropylamine and tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a limitation.
[0109] Compounds of the invention containing basic nitrogen-containing groups may be quaternized using agents such as (C1-C4) alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chlorides, bromides and iodides; di(C1-C4) alkyl sulfates, for example dimethyl, diethyl and diamyl sulfates; (C1-C4) alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chlorides, bromides and iodides; 10 -C 18 ) alkyl halides, such as decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C1-C4) alkyl halides, such as benzyl chloride and phenethyl bromide. Both water-soluble and oil-soluble compounds according to the present invention can be prepared using such salts.
[0110] Preferred pharmaceutically acceptable salts of the above include acetate, trifluoroacetate, benzenesulfonate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a limitation.
[0111] Particularly preferred are the hydrochlorides, dihydrochlorides, hydrobromides, maleates, methanesulfonates, phosphates, sulfates and succinates.
[0112] The acid addition salt of the basic compound of formula I is to contact the free base form with the desired acid of sufficient amount, resulting in the formation of salt in a conventional manner to prepare. The free base can be regenerated by contacting the salt form with a base and separating the free base in a conventional manner. The free base form is different from its corresponding salt form in some aspects about some physical properties (such as solubility in polar solvents); However, for purposes of the present invention, salt corresponds to its free base form separately in other aspects.
[0113] As mentioned above, pharmaceutically acceptable base addition salts of compounds of formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
[0114] The base addition salt of the acidic compound according to the present invention is prepared by contacting the free acid form with a sufficient amount of the desired base, resulting in the formation of a salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and separating the free acid in a conventional manner. The free acid form is different from its corresponding salt form in some aspects with respect to some physical properties (such as solubility in polar solvents); however, for purposes of the present invention, salts correspond to their respective free acid forms in other aspects.
[0115] If the compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses polybasic salts. Typical polybasic salt forms include, for example, bitartrates, diacetates, difumarates, dimeglumine salts, diphosphates, disodium salts and trihydrochlorides, but this is not intended to represent a limitation.
[0116] In relation to the above, it can be seen that the expression "pharmaceutically acceptable salt" herein refers to an active ingredient comprising a compound of formula I in the form of one of its salts, particularly if such salt form confers improved pharmacokinetic properties to the active ingredient compared to the free form of the active ingredient or any other salt form of the active ingredient previously used. A pharmaceutically acceptable salt form of an active ingredient may also provide the active ingredient for the first time with desirable pharmacokinetic properties that it did not previously possess, and may even have a positive effect on its pharmacodynamics with respect to the in vivo therapeutic efficacy of the active ingredient.
[0117] isotope
[0118] Furthermore, it is intended that compounds of formula I include isotopically labeled forms thereof. An isotopically labeled form of a compound of formula I is identical to that compound except for the fact that one or more atoms of the compound have been replaced by one or more atoms having an atomic mass or mass number different from the atomic mass or mass number of the atoms normally found in nature. Examples of isotopes that are readily commercially available and can be incorporated into compounds of formula I by well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, respectively, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of formula I or pharmaceutically acceptable salts thereof containing one or more of the above isotopes and / or other isotopes of other atoms are intended to be part of the present invention. Isotopically labeled compounds of formula I can be used in a variety of beneficial ways. For example, compounds wherein a radioactive isotope such as 3 H or 14 Compounds of Formula I labeled with isotopes of C are suitable for drug and / or substrate tissue distribution assays. These radioactive isotopes, i.e., tritium ( 3 H) and carbon-14 ( 14 C), are particularly preferred due to their ease of preparation and excellent detectability. 2 H) is incorporated into compounds of formula I with therapeutic advantages because such isotopically labeled compounds have higher metabolic stability. Higher metabolic stability translates directly into increased in vivo half-life or lower dosage, which in most cases will represent a preferred embodiment of the present invention. Isotopically labeled compounds of formula I can generally be prepared by implementing the procedures disclosed herein in the synthetic schemes and related descriptions, in the Examples section, and in the Preparation section, by replacing non-isotopically labeled reactants with readily available isotopically labeled reactants.
[0119] Deuterium ( 2H) is incorporated into the compound of formula I for the purpose of controlling the oxidative metabolism of the compound through the primary kinetic isotope effect. The primary kinetic isotope effect is the change in the rate of a chemical reaction caused by isotopic nuclear exchange, which in turn is caused by a change in the ground state energy required to form a covalent bond after such isotopic exchange. The exchange of heavier isotopes generally results in a decrease in the ground state energy of a chemical bond, thereby resulting in a decrease in the rate of rate-limiting bond breakage. If bond breakage occurs in or near a saddle point region along a multi-product reaction coordinate, the product distribution ratio may be significantly altered. For explanation: If deuterium is bonded to a carbon atom at a non-exchangeable site, the typical rate difference is k M / k D = 2-7. If this rate difference is successfully applied to a compound of formula I that is susceptible to oxidation, the distribution of such a compound in the body can be significantly altered and lead to improved pharmacokinetic properties.
[0120] When discovering and developing therapeutic agents, those skilled in the art attempt to optimize pharmacokinetic parameters while maintaining desirable in vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic characteristics are susceptible to oxidative metabolism. Currently available in vitro liver microsomal assays provide valuable information about this type of oxidative metabolic process, which in turn allows for the rational design of deuterated compounds of Formula I with improved stability through resistance to this oxidative metabolism. Significant improvements in the pharmacokinetic characteristics of compounds of Formula I are thereby obtained, and can be achieved in increasing in vivo half-life (t1 / 2), concentration at maximum therapeutic effect (C max ), area under the dose-response curve (AUC), and F, as well as quantitatively expressed in terms of reduced clearance, dose, and material cost.
[0121] The following is intended to illustrate the above: Compounds of formula I having multiple potential oxidative metabolic attack sites (e.g., benzylic hydrogen atoms and hydrogen atoms bonded to nitrogen atoms) are prepared as a series of analogs in which various combinations of hydrogen atoms are replaced by deuterium atoms, such that some, most, or all of these hydrogen atoms are replaced by deuterium atoms. Half-life determinations make it possible to advantageously and accurately determine the extent to which resistance to oxidative metabolism has been improved. In this way, it was determined that the half-life of the parent compound could be extended by up to 100% due to this type of deuterium-hydrogen exchange.
[0122] Deuterium-hydrogen exchange in the compound of formula I can also be used to realize the favorable modification of the metabolite spectrum of the starting compound, to reduce or eliminate undesirable toxic metabolites. For example, if the toxic metabolite is produced by the cleavage of oxidative carbon-hydrogen (CH) bonds, it can be reasonably assumed that the deuterated analog will greatly reduce or eliminate the generation of unwanted metabolites, even if the specific oxidation is not a rate-determining step. Further information on the prior art of deuterium-hydrogen exchange can be found in, for example, Hanzlik et al., J.Org.Chem.55,3992-3997,1990, Reider et al., J.Org.Chem.52,3326-3334,1987, Foster, Adv.Drug Res.14,1-40,1985, Gillette et al., Biochemistry 33 (10) 2927-2937,1994, and Jarman et al. Carcinogenesis 16 (4), 683-688,1993.
[0123] Furthermore, the invention relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants.
[0124] The pharmaceutical preparation can be administered in the form of a dosage unit containing a predetermined amount of active ingredient per dosage unit. Such a unit may contain, for example, 0.5 mg-1 g, preferably 1 mg-700 mg, particularly preferably 5 mg-100 mg of a compound according to the invention, depending on the condition to be treated, the method of administration and the age, weight and condition of the patient, or the pharmaceutical preparation can be administered in the form of a dosage unit containing a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those containing a daily dose or a partial dose as indicated above, or an active ingredient of a corresponding portion thereof. In addition, pharmaceutical preparations of this type can be prepared using methods generally known in the pharmaceutical field.
[0125] The pharmaceutical preparations may be suitable for administration by any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such preparations may be prepared using all methods known in the pharmaceutical art, for example by combining the active ingredient with an excipient or adjuvant.
[0126] Pharmaceutical formulations suitable for oral administration may be administered as discrete units such as capsules or tablets, powders or granules, solutions or suspensions in aqueous or non-aqueous liquids, edible foams or foam foods, or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
[0127] Thus, for example, in the case of oral administration in tablet or capsule form, the active ingredient components may be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient such as ethanol, glycerol, water, etc. Powders are prepared by pulverizing the compound to a suitable fine size and mixing it with a similarly pulverized pharmaceutical excipient such as an edible carbohydrate, such as starch or mannitol. Flavoring agents, preservatives, dispersants and dyes may also be present.
[0128] Capsules are produced by preparing a powder mixture as described above and filling shaped gelatin shells therewith. Glidants and lubricants, such as highly dispersed silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, may be added to the powder mixture before the filling operation. Disintegrants or solubilizers, such as agar, calcium carbonate or sodium carbonate, may also be added to improve the availability of the drug after the capsule is taken.
[0129] In addition, if desired or necessary, suitable binders, lubricants and disintegrating agents and dyes can be incorporated into the mixture equally. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, sweeteners made from corn, natural and synthetic rubbers such as gum arabic, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, wax etc. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride etc. Disintegrating agents include but are not limited to starch, methylcellulose, agar, bentonite, xanthan gum etc. Tablets are prepared by, for example, preparing a powder mixture, granulating the mixture or dry pressing, adding lubricants and disintegrating agents and pressing the whole mixture to obtain tablets. The powder mixture is prepared by mixing the compound pulverized in a suitable manner with a diluent or base as described above and optionally with a binder (such as carboxymethylcellulose, alginate, gelatin or polyvinyl pyrrolidone), a dissolution retardant (such as paraffin), an absorption accelerator (such as a quaternary salt) and / or an absorbent (such as bentonite, kaolin or dicalcium phosphate). The powder mixture can be granulated by wetting it with a binder (such as syrup, starch paste, gum arabic mucus or a solution of cellulose or polymer material) and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tablet press to produce a block of non-uniform shape, which is then broken to form particles. The particles can be lubricated by adding stearic acid, stearate, talc or mineral oil to prevent sticking to the tablet casting mold. The lubricated mixture is then pressed to obtain tablets. The compound according to the present invention can also be combined with a free-flowing inert excipient and then directly pressed to obtain a tablet without granulation or dry pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a wax gloss layer may be present. Dyestuffs can be added to these coatings to allow for differentiation between different dosage units.
[0130] Oral liquids, such as solutions, syrups and elixirs, can be prepared in dosage unit form so that a given amount contains a predetermined amount of compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable taste, while elixirs are prepared using non-toxic alcohol vehicles. Suspensions can be prepared by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers (such as ethoxylated isostearyl alcohol and polyoxyethylene sorbitol ether), preservatives, flavoring additives (such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners) and the like can also be added.
[0131] If desired, dosage unit formulations for oral administration can be encapsulated in microcapsules. The formulations can also be prepared in such a way that the release is prolonged or delayed, for example, by coating or embedding particulate materials in polymers, wax, etc.
[0132] The compounds of formula I and pharmaceutically solvates, salts, tautomers and stereoisomers thereof can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholine.
[0133] Formula I compound and its solvate, salt, tautomer and stereoisomer can also use monoclonal antibody as the separate carrier delivery of compound molecule coupling.These compounds can also be coupled with soluble polymer as targeted drug carrier.This polymer can contain polyvinyl pyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamide phenol, polyhydroxyethyl asparagine phenol or polyethylene oxide polylysine, replaced by palmitoyl.In addition, these compounds can be coupled with a class of biodegradable polymers suitable for realizing controlled release of drugs, such as crosslinking or amphiphilic block copolymers of polylactic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylate and hydrogel.
[0134] Pharmaceutical formulations adapted for transdermal administration may be applied as a separate patch for prolonged, intimate contact with the recipient's epidermis. Thus, for example, the active ingredient may be delivered from the patch by iontophoresis as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).
[0135] Pharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
[0136] For treatment of the eye or other external tissues, for example oral cavity and skin, the formulation is preferably applied as a topical ointment or cream. In the case of formulation to give an ointment, the active ingredient may be used with a paraffinic or water-miscible cream base. Alternatively, the active ingredient may be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
[0137] Pharmaceutical formulations suitable for topical application to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
[0138] Pharmaceutical formulations adapted for topical application in the oral cavity encompass lozenges, pastilles and mouthwashes.
[0139] Pharmaceutical formulations adapted for rectal administration may be administered in the form of suppositories or enemas.
[0140] Pharmaceutical formulations suitable for nasal administration in which the carrier substance is a solid comprise a coarse powder with a particle size, for example, in the range of 20-500 microns, which is administered in the manner of taking a snuff, i.e. by rapid inhalation through the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration with a liquid as carrier substance as nasal spray or nose drops encompass solutions of the active ingredient in water or oil.
[0141] Pharmaceutical formulations adapted for administration by inhalation encompass fine particle dusts or mists which may be generated by various types of pressurized dispensers with nebulizers, atomizers or insufflators.
[0142] Pharmaceutical formulations adapted for vaginal administration may be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
[0143] Pharmaceutical preparations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions, containing antioxidants, buffers, bacteriostats and solutes, whereby the preparations are isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may contain a suspension medium and a thickening agent. The preparations may be administered in single-dose or multi-dose containers, such as sealed ampoules and vials, and stored in a freeze-dried (lyophilized) state, so that only a sterile carrier, such as water for injection purposes, needs to be added before use. Injection solutions and suspensions prepared according to the formula can be prepared from sterile powders, granules and tablets.
[0144] It will be appreciated that in addition to the ingredients particularly mentioned above the formulations may include other agents conventional in the art having regard to the particular type of formulation; thus, for example, formulations suitable for oral administration may include flavoring agents.
[0145] The therapeutically effective amount of formula I compound depends on many factors, including, for example, the age and body weight of the animal, the exact disease and its severity to be treated, the nature and the method of administration of the preparation, and is ultimately determined by the treating doctor or veterinarian. However, the effective amount of the compound according to the present invention is usually in the range of 0.1-100mg / kg recipient (mammal) body weight every day, and particularly generally in the range of 1-10mg / kg body weight every day. Therefore, the actual amount every day for an adult mammal of 70kg body weight is usually between 70-700mg, wherein the amount can be used as a single dose every day or usually with a series of partial doses (such as two, three, four, five or six) every day, so that the total daily dose is the same. The effective amount of its salt or solvate or physiological function derivative can be determined as the fraction of the effective amount of the compound itself according to the present invention. It can be assumed that similar dosage is suitable for the treatment of above-mentioned other diseases.
[0146] Combined treatment of this type can be achieved by means of simultaneous, sequential or separate administration of the individual components of the treatment.Combination products of this type employ the compounds according to the invention.
[0147] The invention furthermore relates to medicaments comprising at least one compound of the formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
[0148] The invention also relates to a set (kit) consisting of the following separate packages:
[0149] (a) an effective amount of a compound of formula I and / or its pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures thereof in all ratios,
[0150] and
[0151] (b) an effective amount of other pharmaceutically active ingredients.
[0152] The kit comprises a suitable container, such as a box, a separate bottle, a bag or an ampoule. For example, the kit may comprise separate ampoules, each containing an effective amount of a compound of formula I and / or a pharmaceutically acceptable salt, tautomer and stereoisomer thereof (including mixtures of all ratios thereof), and an effective amount of other pharmaceutically active ingredients, in dissolved or lyophilized form.
[0153] As used herein, "treating" means alleviating, in whole or in part, the symptoms associated with a disorder or disease, or slowing or halting further progression or worsening of these symptoms, or preventing or prophylaxis of a disease or disorder in a subject at risk of developing the disease or disorder.
[0154] The term "effective amount" in relation to a compound of formula (I) may mean an amount that is capable of alleviating, in whole or in part, the symptoms associated with a disorder or disease, or slowing or stopping the further progression or worsening of these symptoms, or preventing or providing prophylaxis for a disease or disorder in a subject suffering from or at risk of a disease disclosed herein (such as an inflammatory disorder, an immune disorder, a cancer, or a metabolic disorder).
[0155] In one embodiment, the effective amount of the compound of formula (I) is an amount that inhibits HIF-2α in a cell, such as in vitro or in vivo. In some embodiments, an effective amount of the compound of formula (I) inhibits HIF-2α in a cell by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 99% compared to the activity of HIF-2α in untreated cells. For example, in a pharmaceutical composition, the effective amount of the compound of formula (I) may be at a level that will produce the desired effect; for example, a unit dose for both oral and parenteral administration is from about 0.005 mg / kg of the subject's body weight to about 10 mg / kg of the subject's body weight.
[0156] use
[0157] The compounds of the present invention are suitable as pharmaceutically active ingredients for use in mammals, especially humans, in the treatment of cancer.
[0158] The present invention encompasses the use of a compound of formula I and / or a pharmaceutically acceptable salt, tautomer and stereoisomer thereof for the preparation of a medicament for the treatment or prevention of cancer.
[0159] Furthermore, the present invention encompasses compounds of formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof for use in treating or preventing cancer.
[0160] Also contemplated is the use of a compound of formula I and / or a pharmaceutically acceptable solvate, salt, tautomer and stereoisomer thereof for the preparation of a medicament for treating or preventing a HIF-2α-induced disease or a HIF-2α-induced condition in a mammal, wherein for this method, a therapeutically effective amount of a compound according to the invention is administered to a sick mammal in need of such treatment. The therapeutic amount varies depending on the specific disease and can be determined by one skilled in the art without undue effort.
[0161] The present invention specifically relates to the use of compounds of formula I and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for treating diseases in which inhibition, regulation and / or modulation of HIF-2α plays a role.
[0162] The present invention specifically relates to the use of the compound of formula I and its pharmaceutically acceptable salts, solvates, tautomers and stereoisomers, including mixtures thereof in all ratios, for inhibiting HIF-2α.
[0163] Representative cancers that the compounds of Formula I can be used to treat or prevent include, but are not limited to, cancers of the head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, bladder, uterus, cervix, breast, ovary, testicle or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors, and blood-borne tumors.
[0164] In addition, representative cancers that the compounds of Formula I can be used to treat or prevent include glioblastoma, renal cell carcinoma (RCC), and clear cell renal cell carcinoma (ccRCC).
[0165] Furthermore, the present invention encompasses compounds of formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof for use in the treatment or prevention of von Hippel-Lindau (VHL) disease.
[0166] Furthermore, the present invention encompasses compounds of formula I and / or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof for use in the treatment or prevention of cardiovascular diseases.
[0167] Preferably, the present invention relates to a method for treating cancer, comprising administering an effective amount of a compound of formula I according to the present invention to a subject in need thereof.
[0168] Particularly preferably, the present invention relates to a method, wherein the disease is cancer, and wherein the administration is performed simultaneously, sequentially or alternatingly with the administration of at least one other active agent.
[0169] The disclosed compounds of Formula I can be administered in combination with other known therapeutic agents, including anticancer agents.The term "anticancer agent" as used herein relates to any agent that is administered to a patient suffering from cancer for the purpose of treating the cancer.
[0170] The anticancer treatment defined above may be applied as a monotherapy or may involve conventional surgery or radiotherapy or drug therapy in addition to the compounds of formula I disclosed herein. Such drug therapy, such as chemotherapy or targeted therapy, may include one or more, but preferably one, of the following antineoplastic agents:
[0171] Alkylating agents
[0172] Examples include altretamine, bendamustine, busulfan, carmustine, chlorambucil, chlormethine, cyclophosphamide, dacarbazine, ifosfamide, improsulfan, tosilate, lomustine, melphalan, mitobronitol, mitolazone, and ctol), nimustine, ranimustine, temozolomide, thiotepa, treosulfan, mechloretamine, carboquone, apaziquone, fotemustine, glufosfamide, palifosfamide, pipobroman, trofosfamide, uramustine, TH-302 4 、VAL-083 4 ;
[0173] Platinum compounds
[0174] For example, carboplatin, cisplatin, eptaplatin, miriplatin hydrate, oxaliplatin, lobaplatin, nedaplatin, picoplatin, satraplatin;
[0175] DNA altering agents
[0176] For example, amrubicin, bisantrene, decitabine, mitoxantrone, procarbazine, trabectedin, and clofarabine;
[0177] amsacrine, brostallicin, pixantrone, laromustine 1,3 ;
[0178] Topoisomerase inhibitors
[0179] For example, etoposide, irinotecan, razoxane, sobuzoxane, teniposide, and topotecan;
[0180] amonafide, belotecan, elliptiniumacetate, voreloxin;
[0181] Microtubule Modifiers
[0182] For example, cabazitaxel, docetaxel, eribulin, ixabepilone, paclitaxel, vinblastine, vincristine, vinorelbine, vindesine, and vinflunine;
[0183] fosbretabulin, tesetaxel;
[0184] Antimetabolites
[0185] For example, asparaginase 3, azacitidine, calcium levofolinate, capecitabine, cladribine, cytarabine, enocitabine, floxuridine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, nelarabine, pemetrexed, pralatrexate, azathioprine, thioguanine, carmofur;
[0186] doxifluridine, elacytarabine, raltitrexed, sapacitabine, tegafur 2,3 , trimetrexate;
[0187] anticancer antibiotics
[0188] For example, bleomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, levamisole, miltefosine, mitomycin C, romidepsin, streptozocin, valrubicin, zinostatin, zorubicin, daunurobicin, plicamycin; aclarubicin, peplomycin, pirarubicin;
[0189] Hormones / antagonists
[0190] Examples include abarelix, abiraterone, bicalutamide, buserelin, calusterone, chlorotrianisene, degarelix, dexamethasone, estradiol, fluocortolone, fluoxymesterone, flutamide, fulvestrant, and sedative. lvestrant), goserelin, histrelin, leuprorelin, megestrol, mitotane, nafarelin, nandrolone, nilutamide, octreotide, prednisolone, raloxifene, tamoxifen, thyrotropin alfa, toremifene, trilostane, triptorelin, diethylstilbestrol;
[0191] acolbifene, danazol, deslorelin, epitiostanol, orteronel, enzalutamide 1,3 ;
[0192] Aromatase inhibitors
[0193] For example, aminoglutethimide, anastrozole, exemestane, fadrozole, letrozole, and testolactone;
[0194] Formestane;
[0195] Small molecule kinase inhibitors
[0196] For example, crizotinib, dasatinib, erlotinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, vandetanib, vemurafenib, bosutinib, gefitinib, axitinib;
[0197] afatinib, alisertib, dabrafenib, dacomitinib, dinaciclib, dovitinib, enzastaurin, nintedanib, lenvatinib, linifanib, linsitinib, masitinib, midostaurin rin), motesanib, neratinib, orantinib, perifosine, ponatinib, radotinib, rigosertib, tipifarnib, tivantinib, tivozanib, trametinib, pimasertib, brivanib alaninate, cediranib, apatinib 4 , cabozantinib S-malate 1,3 , ibrutinib 1,3 , icotinib 4 , buparlisib 2 , cipatinib 4 , cobimetinib 1,3 , idelalisib 1,3, fedratinib 1 XL-647 4 ;
[0198] Photosensitizer
[0199] For example, methoxsalen 3 ;
[0200] Porfimer sodium, talaporfin, temoporfin;
[0201] Antibody
[0202] For example, alemtuzumab, besilesomab, brentuximab vedotin, cetuximab, denosumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, bevacizumab, and pertuzumab 2,3 ;
[0203] catumaxomab, elotuzumab, epratuzumab, farletuzumab, mogamulizumab, necitumumab, nimotuzumab, obinutuzumab, ocaratuzumab, oregovomab, ramucirumab, rilotumumab, siltuximab, tocilizumab, zalutumumab, zanolimumab, matuzumab, dalotuzumab 1,2,3 , onartuzumab 1,3 , racotumomab 1 , tabalumab1,3 、EMD-525797 4 , avelumab, nivolumab 1,3 ;
[0204] Cytokines
[0205] For example, aldesleukin, interferon α 2 , interferon α2a 3 , interferon α2b 2,3 ; celmoleukin, tasonermin, teceleukin, oprelvekin 1,3 、Recombinant interferon beta-1a 4 ;
[0206] Drug conjugates
[0207] For example, denileukin diftitox, ibritumomab tiuxetan, iobenguane I123, prednimustine, trastuzumab emtansine, estramustine, gemtuzumab, ozogamicin, and aflibercept;
[0208] cintredekin besudotox, edotreotide, inotuzumab ozogamicin, naptumomab estafenatox, oportuzumab monatox, technetium (99mTc), arcitumomab 1,3 , vinblastine-folate conjugate (vintafolide) 1,3 ;
[0209] vaccine
[0210] For example, sipuleucel 3 ; Vitespen 3 、emepepimut-S 3 、oncoVAX 4rindopepimut 3 troVax 4 、MGN-1601 4 、MGN-1703 4 ;
[0211] other
[0212] alitretinoin, bexarotene, bortezomib, everolimus, ibandronic acid, imiquimod, lenalidomide, lentinan, metirosine, mifamurtide, pamidronic acid, pegaspargase, pentostatin, sipuleucel 3 , sizofiran, tamibarotene, temsirolimus, thalidomide, tretinoin, vismodegib, zoledronic acid, vorinostat;
[0213] celecoxib, cilengitide, entinostat, etanidazole, ganetespib, idronoxil, iniparib, ixazomib, lonidamine, nimorazole, panobinostat, peretinoin, plitidepsin, pomalidomide, procodazol, ridaforolimus, tasquinimod, telotristat, thymalfasin, tirapazamine, tosedostat, trabedersen, ubenimex, valspodar, gendicine4 , picibanil 4 , reolysin 4 , retaspimycin hydrochloride 1,3 , trebananib 2,3 , Virulizin 4 , carfilzomib 1,3 , endostatin 4 、immucothel 4 , belinostat 3 、MGN-1703 4 ; PARP inhibitors
[0214] Olaparib, Veliparib.
[0215] 1 Prop.INN (Proposed International Nonproprietary Name)
[0216] 2 Rec.INN (Recommended International Nonproprietary Name)
[0217] 3 USAN (United States adopted name)
[0218] 4 There is no INN.
[0219] The following abbreviations refer to the following definitions:
[0220] aq (aqueous), h (hour), g (gram), L (liter), mg (milligram), MHz (megahertz), min (minute), mm (millimeter), mmol (millimole), mM (millimolar), mp (melting point), eq (equivalent), mL (milliliter), μL (microliter), ACN (acetonitrile), AcOH (acetic acid), CDCl3 (deuterated chloroform), CD3OD (deuterated methanol), c-hex (cyclohexane), DCC (dicyclohexylcarbodiimide) , DCM (dichloromethane), DIC (diisopropylcarbodiimide), DIEA (diisopropylethylamine), DMF (dimethylformamide), DMSO (dimethyl sulfoxide), DMSO-d6 (deuterated dimethyl sulfoxide), EDC (1-(3-dimethyl-amino-propyl)-3-ethylcarbodiimide), ESI (electrospray ionization), EtOAc (ethyl acetate), Et2O (diethyl ether), EtOH (ethanol), HATU (dimethylamino-([1,2 ,3]triazolo[4,5-b]pyridin-3-yloxy)-methylene]-dimethylammonium hexafluorophosphate), HPLC (high performance liquid chromatography), i-PrOH (2-propanol), K2CO3 (potassium carbonate), LC (liquid chromatography), MeOH (methanol), MgSO4 (magnesium sulfate), MS (mass spectrometry), MTBE (methyl tert-butyl ether), NaHCO3 (sodium bicarbonate), NaBH4 (sodium borohydride), NMM (N-methylmorpholine), NMR ( NMR (10-nitrogen nuclear magnetic resonance), PE (petroleum ether), PyBOP (benzotriazol-1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate), RT (room temperature), Rt (retention time), SPE (solid phase extraction), TBTU (2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate), TEA (triethylamine), TFA (trifluoroacetic acid), THF (tetrahydrofuran), TLC (thin layer chromatography), UV (ultraviolet), WL (wavelength).
[0221] Above and below, all temperatures are expressed in ° C. In the following examples, "conventional work-up" means: if necessary, water is added; the pH value is adjusted to a value between 2 and 10, if necessary, depending on the composition of the final product; the mixture is extracted with EtOAc or DCM; the phases are separated; the organic phase is dried over sodium sulfate and evaporated; and the residue is purified by chromatography on silica gel and / or by crystallization. Rf values on silica gel; eluent: EtOAc / MeOH 9:1.
[0222] 1 H NMR was recorded on a Bruker DPX-300, DRX-400, AVII-400 or 500 MHz spectrometer using the residual signal of the deuterated solvent as an internal standard. Chemical shifts (δ) are relative to the residual solvent signal (for DMSO-d6 1H NMR, δ = 2.49 ppm), reported in ppm. 1 H NMR data are reported as follows: Chemical shift (multiplicity, coupling constant and hydrogen number). Multiplicity abbreviations are as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad).
[0223] Analytical methods
[0224] LCMS
[0225] Method A
[0226] Column: Ascentis Express C18, 3.0x50mm, 2.7μm
[0227] Mobile phase: A: water containing 0.05% TFA, B: ACN containing 0.05% TFA
[0228] Gradient: 5% B to 100% B until 2.1 min, hold until 2.8 min, 100% B to 5% B until 2.85 min, stop after 3.00 min
[0229] Flow rate: 1.5mL / min
[0230] Wavelength: 254nm.
[0231] Method B
[0232] Column: Kinetex EVO C18, 3.0x50mm, 2.6μm
[0233] Mobile phase: A: water containing 0.04% NH4OH, B: ACN
[0234] Gradient: 10% B to 95% B until 2.1 min, hold until 2.7 min, 95% B to 10% B until 2.75 min, stop after 3.00 min
[0235] Flow rate: 1.2mL / min
[0236] Wavelength: 254nm.
[0237] Method C
[0238] Column: Ascentis Express C18, 3.0x50mm, 2.7μm
[0239] Mobile phase: A: water containing 0.05% TFA, B: ACN containing 0.05% TFA
[0240] Gradient: 5% B to 60% B until 3.0 min, 60% B to 100% B until 4.2 min, hold until 5.2 min, 100% B to 5% B until 5.3 min, stop after 5.60 min
[0241] Flow rate: 1.5mL / min
[0242] Wavelength: 254nm.
[0243] Method D
[0244] Column: Kinetex EVO C18, 3.0x50mm, 2.6μm
[0245] Mobile phase: A: water containing 0.04% NH4OH, B: ACN
[0246] Gradient: 10% B to 60% B until 3.0 min, 60% B to 95% B until 4.0 min, hold until 4.8 min, 95% B to 10% B until 4.9 min, stop after 5.20 min
[0247] Flow rate: 1.2mL / min
[0248] Wavelength: 254nm.
[0249] Method E
[0250] Column: Cortecs C18+, 2.1x50mm, 2.7μm
[0251] Mobile phase: A: water containing 0.1% FA, B: ACN containing 0.1% FA
[0252] Gradient: 10% B to 100% B until 2.0 min, hold until 2.6 min, 100% B to 10% B until 2.7 min, stop after 2.90 min
[0253] Flow rate: 1.0mL / min
[0254] Wavelength: 254nm.
[0255] Method F
[0256] Column: Shim-pack GIST C18, 3.0x50mm, 2.0μm
[0257] Mobile phase: A: water containing 5 mM NH4CO3, B: ACN
[0258] Gradient: 10% B to 95% B until 2.1 min, hold until 2.7 min, 95% B to 10% B until 2.75 min, stop after 3.00 min
[0259] Flow rate: 1.2mL / min
[0260] Wavelength: 254nm.
[0261] Method G
[0262] Column: Durashell C18, 3.0x50mm, 2.1μm
[0263] Mobile phase: A: water containing 0.04% NH4OH, B: ACN
[0264] Gradient: 10% B to 95% B until 2.1 min, hold until 2.7 min, 95% B to 10% B until 2.75 min, stop after 3.00 min
[0265] Flow rate: 1.2mL / min
[0266] Wavelength: 254nm.
[0267] Method H
[0268] Column: Titank C18, 3.0x50mm, 3.0μm
[0269] Mobile phase: A: water containing 5 mM NH4CO3, B: ACN
[0270] Gradient: 10% B to 95% B until 2.1 min, hold until 2.7 min, 95% B to 10% B until 2.75 min, stop after 3.00 min
[0271] Flow rate: 1.2mL / min
[0272] Wavelength: 254nm.
[0273] Method I
[0274] Column: Poroshell HPH-C18, 3.0x50mm, 2.7μm
[0275] Mobile phase: A: water containing 0.04% NH4OH, B: ACN
[0276] Gradient: 10% B to 95% B until 2.1 min, hold until 2.7 min, 95% B to 10% B until 2.75 min, stop after 3.00 min
[0277] Flow rate: 1.2mL / min
[0278] Wavelength: 254nm.
[0279] Method J
[0280] Column: Cortecs C18+, 2.1x50mm, 2.7μm
[0281] Mobile phase: A: water containing 0.1% FA, B: ACN containing 0.1% FA
[0282] Gradient: 10% B to 60% B until 3.0 min, 60% B to 100% B until 4.0 min, hold until 4.7 min, 100% B to 10% B until 4.8 min, stop after 5.00 min
[0283] Flow rate: 1.0mL / min
[0284] Wavelength: 254nm.
[0285] Method K
[0286] Column: Cortecs C18+, 2.1x50mm, 2.7μm
[0287] Mobile phase: A: water containing 0.1% FA, B: ACN containing 0.1% FA
[0288] Gradient: 10% B to 100% B until 1.10 min, hold until 1.60 min, 100% B to 10% B until 1.61 min, stop after 1.90 min
[0289] Flow rate: 1.0mL / min
[0290] Wavelength: 254nm.
[0291] Method L
[0292] Column: Cortecs C18+, 2.1x50mm, 2.7μm
[0293] Mobile phase: A: water containing 0.1% FA, B: ACN containing 0.1% FA
[0294] Gradient: 5% B to 100% B until 2.0 min, hold until 2.6 min, 100% B to 5% B until 2.7 min, stop after 2.90 min
[0295] Flow rate: 1.0mL / min
[0296] Wavelength: 254nm.
[0297] HPLC
[0298] Method A
[0299] Column: XSELECT HSS T3 100x4.6mm
[0300] Mobile phase: A = water + 0.05% TFA, B = ACN + 0.05% TFA
[0301] Gradient: start 5% B, 95% B after 8 min, 5% B after 10.2 min, stop after 12 min
[0302] Flow rate: 1.2mL / min
[0303] Wavelength: 254nm.
[0304] Method B
[0305] Column: Ascentis Express C18 2.7μm, 100x4.6mm
[0306] Mobile phase: A = water + 0.05% TFA, B = ACN + 0.05% TFA
[0307] Gradient: start 5% B, 95% B after 8 min, 5% B after 10.2 min, stop after 12 min
[0308] Flow rate: 1.5mL / min
[0309] Wavelength: 254nm.
[0310] Analytical Chiral Separation
[0311] Method A
[0312] Method: HPLC
[0313] Column: ChiralPak IG-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=7:3 Wavelength: 254nm
[0314] Flow rate: 1.0mL / min.
[0315] Method B
[0316] Method: HPLC
[0317] Column: ChiralPak IG-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=8:2 Wavelength: 254nm
[0318] Flow rate: 1.0mL / min.
[0319] Method C
[0320] Method: HPLC
[0321] Column: ChiralPak IC-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=7:3 Wavelength: 254nm
[0322] Flow rate: 1.0mL / min.
[0323] Method D
[0324] Method: HPLC
[0325] Column: ChiralPak IF-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=7:3 Wavelength: 254nm
[0326] Flow rate: 1.0mL / min.
[0327] Method E
[0328] Method: HPLC
[0329] Column: ChiralPak IG-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=9:1 Wavelength: 254nm
[0330] Flow rate: 1.0mL / min.
[0331] Method F
[0332] Method: HPLC
[0333] Column: ChiralPak IG-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=6:4 Wavelength: 254nm
[0334] Flow rate: 1.0mL / min.
[0335] Method G
[0336] Method: HPLC
[0337] Column: ChiralPak IC-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / IPA = 1:1
[0338] Wavelength: 254nm
[0339] Flow rate: 1.0mL / min.
[0340] Method H
[0341] Method: HPLC
[0342] Column: ChiralPak IF-3, 0.46x5 cm, 3μm Mobile phase: Hex (10mmol NH3) / EtOH=5:5 Wavelength: 254nm
[0343] Flow rate: 1.0mL / min.
[0344] Method I
[0345] Method: HPLC
[0346] Column: Chiral Cellulose-SB, 0.46x10 cm, 3μm Mobile phase: Hex (0.1% DEA) / IPA = 3:1
[0347] Wavelength: 254nm
[0348] Flow rate: 1.0mL / min.
[0349] Method J
[0350] Method: HPLC
[0351] Column: ChiralPak IG-3, 0.46x5 cm, 3μm Mobile phase: Hex (0.1% DEA) / EtOH=1:1 Wavelength: 254nm
[0352] Flow rate: 1.0mL / min.
[0353] Method K
[0354] Method: HPLC
[0355] Column: ChiralPak IE-3, 0.46x5 cm, 3μm
[0356] Mobile phase: Hex (0.1% DEA) / EtOH = 85:15
[0357] Wavelength: 254nm
[0358] Flow rate: 1.0mL / min.
[0359] Method L
[0360] Method: HPLC
[0361] Column: ChiralPak IC-3, 0.46x5 cm, 3μm
[0362] Mobile phase: Hex (0.1% DEA) / IPA = 65:35
[0363] Wavelength: 254nm
[0364] Flow rate: 1.0mL / min.
[0365] Biological Activity
[0366] Alphascreen Protein-Protein Interaction Assays:
[0367] To evaluate the functional disruption of the PAS B domain interaction of HIF-2α and HIF-1β, an AlphaScreen assay was established. The assay was performed in a 384-well light grey Perkin Elmer microtiter plate in a total volume of 7 μl. Human rec His6Gb1-TEV-GEFKGL-HIF2α(240-350aa)-G(fc 143nM) and human rec ARNTHis6Gb1-TEV-GEFKGL-ARNT(356-470aa)-FLAG-E362R(fc 143nM) were incubated with target compounds (fc 1nM to 30μM) in 20mM Hepes, 150mM NaCl, 0.05% Tween 20, 2mM DTT, 0.1% (w / v) BSA, 0.3% DMSO, pH 7.5 at 23°C for 15 minutes. By adding Anti-FLAG acceptor beads (fc 20 μg / mL) and Nickel chelate donor beads (fc 9 μg / mL) (both Perkin Elmer) were used to detect protein-protein interactions, and the reactions were incubated at 23°C in the dark for 240 minutes. If the donor and acceptor beads are close to each other due to the interaction of HIF2αPAS B with the HIF-1βPAS B domain, a luminescent signal will be generated at 615nm after excitation at 680nm. The PPI-destroying activity of the compound is calculated directly from the loss of the Alphascreen signal. The AlphaScreen signal is measured with an Envision multimode reader (Perkin Elmer LAS Germany GmbH). The control value used is the no inhibitor reaction. The pharmacological zero value used is determined in the absence of HIF-1β. The inhibition value (IC) is calculated using the Assay analyzer from GeneData 50 ).
[0368] The compounds inhibited HIF-2α in the assay with IC 50A<50nM, 50≤B≤1000nM and C>1000nM, as shown in the following table:
[0369]
[0370]
[0371] ITC
[0372] ITC measurements were performed with a VP-ITC microcalorimeter from MicroCal / Malvern (UK). For all titration experiments, the protein and corresponding compound were prepared in 30mM HEPES buffer pH 7.5, 150mM NaCl and 5mM β-mercaptoethanol. Protein HIF2α (240-350)-G was prepared by recombinant overexpression and multi-step chromatography purification. Compounds were used from concentrated DMSO stock solutions. The final protein concentration in the syringe was 100 μM. The 10mM ligand stock solution in DMSO was diluted to a 10 μM concentration with buffer and loaded into the sample cell. All buffers were adjusted to a final concentration of 1% (v / v) DMSO. Both the titrant and the titrant solution were degassed before loading the calorimeter cell and the syringe. ITC titrations were performed at a constant temperature of 303K. ITC data analysis was performed using a custom calorimeter based on Origin 7 (Origin Lab Cooperation Northampton, USA) provided by MicroCal / Malvern (UK) as standard instrument software. The integrated thermal data were fit with a single-site binding model to determine apparent values for affinity, enthalpy and stoichiometry of binding.
[0373] Compounds bind HIF-2α in assays where K D A<100nM, 100≤B≤1000nM and C>1000nM, as shown in the following table:
[0374] Examples ITC 1a B 3a B 5a B 7a A 8a B 9a B 12a B 13a B 16a B 19a A 20a B 22a B 24a C 25a C 26a C 27a B 28a B 29a C 30a C 31a C
[0375] Cellular Mechanistic Assay: 786-O HRE-luc2P Reporter Gene Assay
[0376] The reporter gene assay is designed to monitor the binding of the HIF2α-HIF1β complex to a specific DNA fragment called the hypoxia response element (HRE) in a physiologically relevant cell line. The 786-O HRE-luc2P cell is derived from the 786-O human renal cell adenocarcinoma cell line by stably integrating the HRE Luc reporter gene construct (pGL4.42 [luc2P / HRE / Hygro] Vector, Promega, cat no. E4001) that drives luciferase expression under the control of the HRE sequence. HRE is present in the promoters of various genes regulated by hypoxia-inducible factors. 786-O cells only express HIF2α. Therefore, the reporter gene assay allows monitoring HIF2α-HIF1β activity by determining the activity of the luciferase produced. Cell culture is carried out in RPMI medium supplemented with 10% FBS, sodium pyruvate, penicillin / streptomycin, glutamine, 200μg / mL hygromycin-gold.
[0377] The assay was performed in 384-well white opaque microtiter plates with clear bottoms (Greiner Bio-one, Frickenhausen). 786-O HRE-luc2P cells were plated at 4 x 10 4 10 cells / mL were resuspended in fresh, pre-warmed medium without hygromycin (RPMI, 10% FBS, SP, P / S, Q). 50 μl of cell suspension (2000 cells) was dispensed into microtiter plates per well and incubated overnight at 37°C in a 5% CO2 incubator. Compounds (fc 0.3% DMSO, 9 dilutions of stock starting at 30 μM) were added using a Labcyte Echo dispenser. The plates were incubated at 37°C in a 5% CO2 incubator for 48 hours. Afterwards, 45 μl of pre-warmed ONE-Glo was added to each well. TM EX reagent. The plate was placed on an orbital shaker at 1200 rpm for 3 minutes. The plate was sealed and luminescence was measured with a Tecan Spark 20M microplate reader (endpoint measurement with a read time of 0.1 seconds). Values were normalized to DMSO controls and wells without cells (medium only controls). The reduction in luminescence was directly related to the inhibition of HIF2α activity. EC was calculated using Ryvu Therapeutics (formerly Selvita SA) DRC application or GraphPad Prism software fitting a variable slope sigmoidal function 50 Values and effect size percentages.
[0378] The compounds inhibited HIF-2α in the assay with IC 50 A<50nM, 50≤B≤1000nM and C>1000nM, as shown in the following table:
[0379] Examples HRE-luc2P reporter gene assay 1a B 2a B 3a B 4a B 5a B 6a A 7a B 8a B 9a C 10a C 11a B 12a B 13a C 14a B 15a B 16a C 17a B 18a B 19a B 20a B 21a B 23a C 24a C 25a C 26a C 27a C 28a C 29a C 30a C 31a C 32a C 33a B 34a C
[0380] synthesis
[0381] General Procedure
[0382]
[0383] Synthesis of 3-(2,5-dichlorothiophen-3-yl)propionic acid (2)
[0384]
[0385] To 3-(Thiophen-3-yl)propanoic acid (6.00 g, 36.49 mmol, 95%) in a 250 ml round bottom flask was added toluene (70 ml) and SO2Cl2 (11.92 g, 83.90 mmol, 95%). The resulting solution was stirred at 69 °C for 4 h. The reaction was then quenched by adding 100 mL of water / ice and extracted with 4 x 100 mL of EtOAc. The combined organic layers were dried over sodium sulfate, filtered and the solvent evaporated. The residue was purified by column chromatography eluting with 0-8% EtOAc in PE to give 8.89 g of 3-(2,5-dichlorothiophen-3-yl)propanoic acid as a colorless solid.
[0386] 1 H NMR (400 MHz, DMSO-d6): δ 12.00 (s, 1H), 7.07 (s, 1H), 2.75-2.70 (m, 2H), 2.54-2.48 (m, 2H); LC-MS (Method D): [MH]-=222.75, Rt=0.89 min.
[0387] Synthesis of 3-(2,5-dichlorothiophen-3-yl)propionyl chloride (3)
[0388]
[0389] To 3-(2,5-dichlorothiophen-3-yl)propanoic acid (8.89 g, 36.89 mmol, 93.4%) in a 250 mL round bottom flask purged with nitrogen was added thionyl chloride (80.00 mL, 1.05 mol, 95%). The resulting solution was stirred at 25 °C for 3 h. The mixture was then concentrated under reduced pressure to give 8.32 g of 3-(2,5-dichlorothiophen-3-yl)propanoyl chloride as an orange oil, which was used without further purification.
[0390] Synthesis of 1,3-dichloro-5H,6H-cyclopenta[c]thiophene-4-one (4)
[0391]
[0392] In a 500 mL round bottom flask purged with nitrogen, 3-(2,5-dichlorothiophen-3-yl)propanoyl chloride (8.32 g, 32.04 mmol, 93.8%) was dissolved in DCM (80 mL) and the solution was cooled to 0-5°C. AlCl3 (35.98 g, 256.3 mmol, 95%) was added slowly. The resulting mixture was stirred at 25°C for 5 h. It was then poured into 1 L water / ice and extracted with 3x300 mL EtOAc. The combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated. The residue was purified by column chromatography eluting with EtOAc (0-10%) in PE to give 4.02 g of 1,3-dichloro-5H,6H-cyclopenta[c]thiophene-4-one as a light yellow solid.
[0393] 1 H NMR (400 MHz, CDCl3): δ 3.01-2.95 (m, 2H), 2.87-2.81 (m, 2H); LC-MS (method D): [M+H] + =206.80,Rt=0.95min.
[0394] Synthesis of 1-chloro-3-(methylthio)-4H,5H,6H-cyclopenta[c]thiophene-4-one
[0395]
[0396] To a 250-mL round-bottom flask purged with nitrogen was added 1,3-dichloro-5H,6H-cyclopenta[c]thiophene-4-one (4.57 g, 21.10 mmol), tetrahydrofuran (97 mL) and (methylthio)sodium (1.77 g, 23.99 mmol). The resulting solution was stirred at 25 °C for 4 h. The reaction was then quenched by the addition of H2O. The resulting solution was extracted with 100 mL of ethyl acetate. The organic layer was dried, filtered and the solvent evaporated. The residue was loaded onto a silica gel column with ethyl acetate / petroleum ether (1:20) to give 3.3 g (71%) of 1-chloro-3-(methylthio)-4H,5H,6H-cyclopenta[c]thiophene-4-one as a red solid. LC-MS (Method K): [M+H] + =218.85,Rt=0.92min.
[0397] Synthesis of 1-chloro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-one
[0398]
[0399] Into a 50-mL round-bottom flask purged and maintained with an inert nitrogen atmosphere was placed 1-chloro-3-(methylthio)-4H,5H,6H-cyclopenta[c]thiophene-4-one (3.3 g, 15.0 mmol), dichloromethane (31 mL) and m-CPBA (17.2 g, 74.75 mmol, 75%). The resulting solution was stirred at 25 °C for 2 h and quenched with water. The resulting solution was extracted with 4x50 mL of ethyl acetate and the organic layers were combined, dried over sodium sulfate, filtered and concentrated in vacuo to give 3.3 g (85%) of 1-chloro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-one as a white solid. LC-MS (Method K): [M+H] + =250.85,Rt=0.71min.
[0400] Synthesis of 1-chloro-3-methylsulfonyl-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2'-[1,3]dioxolane]
[0401]
[0402] Into a 250-mL round-bottom flask purged with nitrogen was placed 1-chloro-3-methanesulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-one (3.00 g, 10.0 mmol), ethane-1,2-diol (1.30 g, 20.0 mmol), TsOH (0.36 g, 1.996 mmol), and toluene (100 mL). The resulting solution was stirred at 125 ° C for 16 h. The resulting mixture was concentrated and the residue was purified by column chromatography (ethyl acetate: petroleum ether = 1:3). This produced 2.8 g (94%) of 1-chloro-3-methanesulfonyl-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2'-[1,3]dioxolane] as a yellow solid. LC-MS (Method K): [M+H] + =294.95,Rt=0.94min.
[0403] Synthesis of 3-methanesulfonyl-1-(2-methylpropoxy)-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2'-[1,3]dioxolane]
[0404]
[0405] 2-Methylpropan-1-ol (1286 mg, 16.5 mmol) and DMF (20 mL) were placed in a 20-mL vial purged with nitrogen. Potassium isobutoxide (1.04 g, 8.8 mmol) was then added. The mixture was stirred at 0 ° C for 20 min. 1-Chloro-3-methanesulfonyl-5,6-dihydrospiro[cyclopentadiene [c] thiophene-4,2'-[1,3] dioxolane] (900 mg, 2.75 mmol) and 15-crown ether-5 (955.71 mg, 4.1 mmol) were added thereto. The resulting solution was stirred at 55 ° C for 3 h in an oil bath, cooled to room temperature and quenched with water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers were combined, filtered and concentrated in vacuo. The residue was added to a silica gel column with ethyl acetate / petroleum ether (1:4). This resulted in 566 mg (53%) of 3-methylsulfonyl-1-(2-methylpropoxy)-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2′-[1,3]dioxolane as a brown solid. LC-MS (Method K): [M+H] + =333.05,Rt=1.06min.
[0406] Synthesis of 3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one
[0407]
[0408] Into a 100-mL round-bottom flask was placed 3-methylsulfonyl-1-(2-methylpropoxy)-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2'-[1,3]dioxolane] (556 mg, 1.5 mmol), DCM (10 mL) and TFA (1.5 mL, 19.2 mmol). The resulting solution was stirred at 25 °C for 3 h. The reaction was then quenched by the addition of 30 mL of NaHCO3. The resulting solution was extracted with ethyl acetate and the combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. This produced 500 mg (74.9% purity, 86%) of 3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one as a brown solid. LC-MS (Method K): [M+H] + =288.95,Rt=0.94min.
[0409] Synthesis of 5-Fluoro-3-methanesulfonyl-4,4-dimethoxy-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene
[0410]
[0411] Into a 20-mL vial purged and maintained with an inert nitrogen atmosphere was placed 3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one (560 mg, 1.45 mmol, 74.9%), MeOH (10 mL), selective fluorine reagent (1376 mg, 3.7 mmol), H2SO4 (0.25 mL, 4.5 mmol). The resulting solution was stirred at 60 °C in an oil bath for 3 h. The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers were combined, filtered and concentrated in vacuo. This produced 550 mg (39% purity, 42%) of 5-fluoro-3-methylsulfonyl-4,4-dimethoxy-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene as a brown solid. LC-MS (Method K): [M+H-CH3-OCH3] + =306.95,Rt=1.09min.
[0412] Synthesis of 5-Fluoro-3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one
[0413]
[0414] Into a 100-mL round bottom flask was placed 5-fluoro-3-methanesulfonyl-4,4-dimethoxy-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene (550 mg, 0.858 mmol, 39%), DCM (10 mL), TFA (2 mL, 25.580 mmol). The resulting solution was stirred at 25 °C for 2 h. The reaction was then quenched by the addition of water. The resulting mixture was extracted with 3x20 mL of ethyl acetate and the organic layers were combined, filtered and concentrated in vacuo. This produced 520 mg (45% purity, 89%) of 5-fluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one as a solid. LC-MS (Method K): [M+H] + =306.95,Rt=1.10min.
[0415] Synthesis of tert-butyl({[5-fluoro-1-methanesulfonyl-3-(2-methylpropoxy)-4H-cyclopenta[c]thien-6-yl]oxy})dimethylsilane
[0416]
[0417] Into a 50-mL three-necked round-bottom flask purged with nitrogen was placed 5-fluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one (100 mg, 0.29 mmol), DCM (5 mL), TEA (160 mg, 1.50 mmol, 95%), TBSOTf (252 mg, 0.91 mmol). The resulting mixture was stirred at room temperature for 3 h and then concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 1:5). This produced 100 mg (74%) of tert-butyl ({[5-fluoro-1-methanesulfonyl-3-(2-methylpropoxy)-4H-cyclopenta[c]thiophene-6-yl]oxy})dimethylsilane as a yellow oil. LC-MS (Method K): [M+H] + =421.10,Rt=1.36min.
[0418] Synthesis of 5,5-difluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one
[0419]
[0420] Into a 25-mL round bottom flask was placed tert-butyl({[5-fluoro-1-methanesulfonyl-3-(2-methylpropoxy)-4H-cyclopenta[c]thiophen-6-yl]oxy})dimethylsilane (90 mg, 0.19 mmol), MeCN (4 mL), selective fluorine reagent (151.5 mg, 0.41 mmol). The resulting solution was stirred at room temperature for 2 h. The resulting solution was diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 2x30 mL of aqueous NaCl solution, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. This produced 60 mg (86%) of 5,5-difluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophen-4-one as a yellow solid. LC-MS (Method K): [M+H] + =325.05,Rt=0.97min.
[0421] Synthesis of 5,5-difluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol
[0422]
[0423] Into a 25-mL round-bottom flask was placed 5,5-difluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-one (30 mg, 0.08 mmol), THF (4 mL), NaBH4 (7.0 mg, 0.18 mmol). The resulting solution was stirred at room temperature for 2 h and diluted with 30 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NaCl aqueous solution, dried over anhydrous sodium sulfate, filtered and concentrated. 5,5-difluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol was obtained as a white solid.
[0424] Chiral Resolution of 5,5-Difluoro-3-methanesulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (8)
[0425]
[0426] 5,5-Difluoro-3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (8) was separated by chiral preparative HPLC under the following conditions: HPLC column: ChiralPak IG-3, 0.46×5 cm, 3 μm, mobile phase: Hex (0.1% DEA) / EtOH=9:1, wavelength: 254 nm, flow rate: 1.0 mL / min. This produced 30.3 mg of (4S)-5,5-difluoro-3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (8a) as a white solid, melting point 65-68° C.
[0427] 8a: 1 H NMR (300MHz, CD3OD): δ = 5.04 (dd, J = 11.6, 2.8Hz, 1H), 3.97 (d, J = 6.5Hz, 2H), 3.25 (s, 3H), 3.2 4-3.12(m,2H),2.18-2.00(m,1H),1.03(d,J=6.7Hz,6H); LC-MS (Method E): Rt=1.24min,[M+HCOO] - =370.75; HPLC (method B): purity 99.1%, Rt 5.28 min; chiral HPLC (method E): 98.0%er, Rt 3.95 min, (8b: Rt=3.53 min).
[0428] The following compounds have been obtained similarly:
[0429] (4S)-1-(Cyclohexyloxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (1a)
[0430]
[0431] Prepare according to the general procedure; 1 H NMR (300MHz, CD3OD): δ=5.06-5.02(m,1H),4.31-4.23(m,1H),3.27(s,3H),3.21-3.08(m,2H),2.06 (m,2H),1.80-1.74(m,2H),1.66-1.58(m,3H),1.52-1.35(m,3H); LC-MS (Method A): Rt=1.47min,[M+Na] + =274.9; HPLC (method A): purity 99.7%, Rt 6.70min; chiral HPLC (method A):>99.5%ee, Rt 2.2min.
[0432] The (4R)-enantiomer was obtained analogously.
[0433] (4S)-1-(2,2-dimethylpropoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (2a)
[0434]
[0435] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 5.06 (dd, J = 11.5, 2.9 Hz, 1H), 3.88 (s, 2H), 3.28 (s, 3H), 3.23 (ddd, J = 16.2, 9.0, 5.4 Hz, 2H), 1.06 (s, 9H); LC-MS (method B): Rt = 1.66 min, [M+NH4] + =358.1; HPLC (method B): purity 98.6%, Rt 5.72min; chiral HPLC (method B):>99.5%ee, Rt 1.53min.
[0436] The (4R)-enantiomer was obtained analogously.
[0437] (4S)-1-Cyclobutoxy-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (3a)
[0438]
[0439] Prepare according to the general procedure; 1 H NMR (300MHz, CD3OD): δ=5.06-5.02(m,1H),4.80-4.73(m,1H),3.26-3.14(m,5H),2.55-2.45(m, 2H), 2.31-2.18 (m, 2H), 1.95-1.85 (m, 1H), 1.78-1.68 (m, 1H); LC-MS (method A): Rt=1.52min, [M+Na] + =346.9; HPLC (method A): purity 99.5%, Rt 6.0 min; chiral HPLC (method B): 99.8% er, Rt 2.26 min.
[0440] The (4R)-enantiomer was obtained analogously.
[0441] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(2-methylbutyloxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (4a)
[0442]
[0443] Prepare according to the general procedure; 1 H NMR (300MHz, CD3OD): δ = 5.06 (dd, J = 11.4, 2.7Hz, 1H), 4.08-3.96 (m, 2H), 3.31 (s, 3H), 3.22-3.14 (m, 2H), 1. 94-1.83(m,1H),1.62-1.48(m,1H),1.36-1.21(m,1H),1.03-0.93(m,6H); LC-MS (Method C): Rt=2.75min, [M+Na] + =363.0; HPLC (method A): purity 97.4%, Rt 6.75min; chiral HPLC (method C):>99.5%ee, Rt 1.24min.
[0444] The (4R)-enantiomer was obtained analogously.
[0445] (4S)-1-(2,2-difluoroethoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (5a)
[0446]
[0447] Prepare according to the general procedure; 1H NMR (300 MHz, DMSO-d6): δ = 6.69 (m, 1H), 6.56-6.21 (m, 1H), 4.97 (m, 1H), 4.62-4.52 (m, 2H), 3.44-3.28 (m, 5H); LC-MS (method A): Rt = 1.06 min, [M+Na] + =356.8; HPLC (method A): purity 99.9%, Rt 5.16min; chiral HPLC (method A): 99.5%ee, Rt 1.9min.
[0448] The (4R)-enantiomer was obtained analogously.
[0449] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(3,3,3-trifluoro-2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (6a)
[0450]
[0451] Prepare according to the general procedure; 1 H NMR (300MHz, DMSO-d6): δ = 6.69 (d, J = 7.1Hz, 1H), 5.03-4.87 (m, 1H), 4.34 (d, J = 5.4Hz, 2H), 3.28 ( d, J=5.6Hz, 5H), 2.97 (d, J=7.6Hz, 1H), 1.18 (d, J=7.1Hz, 3H); LC-MS (method D): Rt=2.52min, [M+NH4] + =398.1; HPLC (method A): purity 99.5%, Rt 6.20min; chiral HPLC (method B):>99.5%ee, Rt 2.13min.
[0452] The (4R)-stereoisomer has been obtained analogously.
[0453] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(2,2,2-trifluoroethoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (7a)
[0454]
[0455] Prepare according to the general procedure; 1 H NMR (300 MHz, DMSO-d6): δ = 5.08 (d, J = 6.9 Hz, 1H), 5.07-4.99 (m, 3H), 3.40-3.35 (m, 5H); LC-MS (method E): Rt = 1.14 min, [M+HCOO]- =396.7; HPLC (method A): purity 99.6%, Rt 5.6min; chiral HPLC (method D):>99.5%ee, Rt 1.22min.
[0456] The (4R)-enantiomer was obtained analogously.
[0457] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(2-methylpropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (8a)
[0458]
[0459] Prepare according to the general procedure; 1 H NMR (300MHz, CD3OD): δ = 5.04 (dd, J = 11.6, 2.8Hz, 1H), 3.97 (d, J = 6.5Hz, 2H), 3.25 (s, 3H), 3.2 4-3.12(m,2H),2.18-2.00(m,1H),1.03(d,J=6.7Hz,6H); LC-MS (Method E): Rt=1.24min,[M+HCOO] - =370.75; HPLC (method B): purity 99.1%, Rt 5.28min; chiral HPLC (method E): 98.0%er, Rt 3.95min.
[0460] The (4R)-enantiomer was obtained analogously.
[0461] (4S)-5,5-Difluoro-3-methanesulfonyl-1-{[1,1,1-trifluorobutan-2-yl]oxy}-4H,5H,6H-cyclopenta[c]thiophene-4-ol (9a)
[0462]
[0463] Prepare according to the general procedure; 1 H NMR (400 MHz, CD3OD): δ = 5.08 (dd, J = 11.1, 3.0 Hz, 1H), 4.74-4.65 (m, 1H), 3.28 (s, 3H), 3.26-3.18 (m, 2H), 2.01-1.83 (m, 2H), 1.13 (t, J = 7.6 Hz, 3H); LC-MS (method E): Rt = 1.44 min, [M+HCOO] - =424.75; HPLC (method B): purity 99.6%, Rt 5.44 min; chiral HPLC (method B): 99.8% er, Rt 2.36 min.
[0464] In the formula, "or" means unknown configuration.
[0465] Stereoisomers have been obtained similarly.
[0466] (4S)-1-{[1,1-difluoropropan-2-yl]oxy}-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (10a)
[0467]
[0468] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 6.18-5.81 (m, 1H), 5.08-5.03 (m, 1H), 4.62-4.47 (m, 1H), 3.29-3.14 (m, 5H), 1.45 (s, 3H); LC-MS (method D): Rt = 2.14 min, [M+NH4] + =366.0; HPLC (method B): purity 96.5%, Rt 4.50min; chiral HPLC (method A): >99.5%ee, Rt 2.17min.
[0469] In the formula, "or" means unknown configuration.
[0470] Stereoisomers have been obtained similarly.
[0471] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(3,3,3-trifluoropropoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (11a)
[0472]
[0473] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 5.07 (dd, J = 11.5, 3.0 Hz, 1H), 4.44 (t, J = 5.8 Hz, 2H), 3.29 (s, 3H), 3.26-3.19 (m, 2H), 2.86-2.71 (m, 2H); LC-MS (method B): Rt = 1.41 min, [M+NH4] + =384.0; HPLC (method A): purity 96.1%, Rt 4.74min; chiral HPLC (method B):>99.5%, Rt 1.61min.
[0474] The (4R)-enantiomer was obtained analogously.
[0475] (4S)-5,5-Difluoro-3-methylsulfonyl-1-propoxy-4H,5H,6H-cyclopenta[c]thiophene-4-ol (12a)
[0476]
[0477] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 5.08 (m, 2H), 4.19-4.15 (m, 2H), 3.25-3.11 (m, 5H), 1.91-1.80 (m, 2H), 1.08-1.06 (m, 3H); LC-MS (method F): Rt = 1.77 min, [MH] - =311.0; HPLC (method A): purity 98.9%, Rt 5.91min; chiral HPLC (method F):>99.5%ee, Rt1.10min.
[0478] The (4R)-enantiomer was obtained analogously.
[0479] (4S)-1-(Cyclopropylmethoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (13a)
[0480]
[0481] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 5.08 (dd, J = 11.1, 3.0 Hz, 1H), 4.05 (d, J = 7.2 Hz, 2H), 3.27-3.15 (m, 5H), 1.39-1.26 (m, 1H), 0.71-0.60 (m, 2H), 0.45-0.39 (m, 2H); LC-MS (method G): Rt = 1.41 min, [M+NH4] + =342.1; HPLC (method A): purity 99.8%, Rt 5.79 min; chiral HPLC (method B): >99.5% ee, Rt 5.45 min.
[0482] The (4R)-enantiomer was obtained analogously.
[0483] (4S)-1-{[1,1-difluoropropan-2-yl]oxy}-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (14a)
[0484]
[0485] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 6.19-5.81 (m, 1H), 5.08-5.03 (m, 1H), 4.62-4.47 (m, 1H), 3.30-3.14 (m, 5H), 1.44 (s, 3H); LC-MS (method D): Rt = 2.14 min, [M+NH4] + =366.1; HPLC (method B): purity 96.8%, Rt 4.52min; chiral HPLC (method A):>99.5%ee, Rt1.74min.
[0486] In the formula, "or" means unknown configuration.
[0487] Stereoisomers have been obtained similarly.
[0488] (4S)-1-(2,2-difluoropropoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (15a)
[0489]
[0490] Prepare according to the general procedure; 1 H NMR (400 MHz, CDCl3): 5.24 (dd, J = 11.5, 4.8 Hz, 1H), 4.28-4.20 (t, J = 11.2 Hz, 2H), 3.40-3.14 (m, 6H), 1.78 (t, J = 18.8 Hz, 3H); LC-MS (method H): Rt = 1.62 min, [MH]- = 346.9; HPLC (method B): purity 99.5%, Rt 4.7 min; chiral HPLC (method A): >99.5% ee, Rt 2.21 min.
[0491] The (4R)-enantiomer was obtained analogously.
[0492] (4S)-5,5-Difluoro-3-methylsulfonyl-1-[(1-methoxycyclobutyl)methoxy]-4H,5H,6H-cyclopenta[c]thiophene-4-ol (16a)
[0493]
[0494] Prepare according to the general procedure; 1H NMR (300 MHz, CD3OD): δ=5.08 (dd, J=11.4, 2.7 Hz, 1H), 4.33 (s, 2H), 3.36-3.30 (m, 4H), 3.28-3.17 (m, 4H), 2.30-2.19 (m, 2H), 2.11-2.03 (m, 2H), 1.90-1.67 (m, 2H); LC-MS (method E): Rt=1.09 min, [M+COO]-=412.8; HPLC (method A): purity 99.8%, Rt 5.71 min; chiral HPLC (method A): >99.5% ee, Rt 1.55 min.
[0495] The (4R)-enantiomer was obtained analogously.
[0496] (4S,5S)-5-Fluoro-3-methylsulfonyl-1-(2,2,2-trifluoroethoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (17a)
[0497]
[0498] Prepare according to the general procedure; 1 H NMR (400 MHz, CD3OD): δ=5.39-5.19 (m, 2H), 4.79-4.73 (m, 2H), 3.37-3.32 (m, 3H), 3.15-3.03 (m, 2H); LC-MS (method B): Rt=1.24 min, [MH]-=332.9; HPLC (method B): purity 98.0%, Rt 4.08 min; chiral HPLC (method A):>99.5% ee, Rt 3.67 min.
[0499] Stereoisomers have been obtained similarly.
[0500] (4S)-1-[(3,3-difluorocyclobutyl)methoxy]-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (18a)
[0501]
[0502] Prepare according to the general procedure; 1H NMR (300 MHz, DMSO-d6): δ = 6.68 (d, J = 7.0 Hz, 1H), 5.06-4.88 (m, 1H), 4.28 (d, J = 6.0 Hz, 2H), 3.29 (d, J = 16.1 Hz, 5H), 2.83-2.57 (m, 3H), 2.49 (s, 2H); LC-MS (method B): Rt = 1.49 min, [M+NH4] + =392.1; HPLC (method B): purity 99.5%, Rt 4.98 min; chiral HPLC (method A): >99.5% ee, Rt 1.42 min.
[0503] The (4R)-enantiomer was obtained analogously.
[0504] (4S)-1-(Cyclobutylmethoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (19a)
[0505]
[0506] Prepare according to the general procedure; 1 H NMR (300MHz, CD3OD): δ = 5.08 (dd, J = 2.7Hz, 1H), 4.18 (d, J = 6.3Hz, 2H), 3.27 (s, 3H), 3.24-3.16 (m ,2H),2.88-2.78(m,1H),2.21-2.09(m,2H),2.06-1.80(m,4H); LC-MS (Method E): Rt=1.28min,[M+Na] + =362.0; HPLC (method A): purity 99.8%, Rt 6.47 min; chiral HPLC (method A): >99.5% ee, Rt 2.20 min.
[0507] The (4R)-enantiomer was obtained analogously.
[0508] (4S)-1-(1-Cyclobutylethoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (20a)
[0509]
[0510] Prepare according to the general procedure; 1H NMR (300MHz, CD3OD): δ = 5.08 (dd, J = 11.7, 2.7Hz, 1H), 4.31-4.23 (m, 1H), 3.29-3.06 (m, 5H), 2.64-2.51(m,1H),2.07-1.77(m,6H),1.28(d,J=6Hz,3H); LC-MS (Method E): Rt=1.41min,[2M+H] + =705.1; HPLC (method A): purity 99.4%, Rt 6.78 min; chiral HPLC (method B): 99.2% er, Rt 1.45 min.
[0511] Stereoisomers have been obtained similarly.
[0512] (4S)-1-(3,3-difluorobutoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (21a)
[0513]
[0514] Prepare according to the general procedure; 1 H NMR (300 MHz, DMSO-d6): δ = 6.71 (d, J = 7.0 Hz, 1H), 5.06-4.92 (m, 1H), 4.43-4.32 (m, 2H), 3.34 (s, 3H), 3.31-3.19 (m, 2H), 2.49-2.36 (m, 2H), 1.76-1.61 (m, 3H); LC-MS (method H): Rt = 2.86 min, [M+NH4] + =380.0; HPLC (method B): purity 97.4%, Rt 4.71 min; chiral HPLC (method A): >99.5% ee, Rt 1.25 min.
[0515] The (4R)-enantiomer was obtained analogously.
[0516] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(oxan-4-yloxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (22a)
[0517]
[0518] Prepare according to the general procedure; 1H NMR (300 MHz, CD3OD): δ = 5.08-5.04 (m, 1H), 4.55-4.47 (m, 1H), 3.99-3.91 (m, 2H), 3.63-3.55 (m, 2H), 3.32-3.14 (m, 5H), 2.14-2.08 (m, 2H), 1.86-1.75 (m, 2H); LC-MS (method F): Rt = 1.35 min, [M+Na] + =376.9; HPLC (method A): purity 99.9%, Rt 4.96 min; chiral HPLC (method G): >99.5% ee, Rt 2.07 min.
[0519] The (4R)-enantiomer was obtained analogously.
[0520] (4S)-5,5-Difluoro-3-methylsulfonyl-1-[2-(trifluoromethoxy)ethoxy]-4H,5H,6H-cyclopenta[c]thiophene-4-ol (23a)
[0521]
[0522] Prepare according to the general procedure; 1 H NMR (400 MHz, CD3OD): δ = 5.07 (dd, J = 11.4, 3.0 Hz, 1H), 4.48-4.42 (m, 2H), 4.42-4.35 (m, 2H), 3.29 (s, 3H), 3.36-3.15 (m, 2H); LC-MS (method B): Rt = 2.42 min, [M+NH4] + =400.0; HPLC (method B): purity 99.0%, Rt 4.90 min; chiral HPLC (method E): >99.5% ee, Rt 2.71 min.
[0523] The (4R)-enantiomer was obtained analogously.
[0524] 1-(3,4-Difluorophenoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol (24a)
[0525]
[0526] Prepare according to the general procedure; 1H NMR (300MHz, CDCl3): δ=7.23-7.17(m,1H),7.05-6.98(m,1H),6.93-6.87(m,1H),5.27-5 .21(m,1H),3.49(s,1H),3.26(s,3H),3.19-2.96(m,2H); LC-MS (Method E): Rt=1.24min,[M+H] + =404.9; HPLC (method A): purity 99.3%, Rt 6.44min; racemate.
[0527] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(propan-2-yloxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (25a)
[0528]
[0529] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 5.05 (m, 1H), 4.53 (m, 1H), 3.28-3.25 (s, 3H), 3.24-3.13 (m, 2H), 1.42 (d, 6H); LC-MS (method I): Rt = 1.37 min, [M+NH4] + =330.0; HPLC (method B): purity 99.8%, Rt 4.4 min; chiral HPLC (method G):>99.5%ee, Rt 1.38 min.
[0530] The (4R)-enantiomer was obtained analogously.
[0531] 3-Chloro-5-{[(4S)-5,5-difluoro-4-hydroxy-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thien-1-yl]oxy}benzonitrile (26a)
[0532]
[0533] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 7.69 (t, 1H), 7.59-7.54 (m, 2H), 5.14 (m, 1H), 3.34 (s, 3H), 3.11 (m, 2H); LC-MS (method E): Rt = 1.29 min, [M+Na] + =429.0; HPLC (method A): purity 99.9%, Rt 6.45min; chiral HPLC (method G):>99.5%ee, Rt 1.70min.
[0534] The (4R)-enantiomer was obtained analogously.
[0535] (4S)-1-(3,5-difluorophenoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol (27a)
[0536]
[0537] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 7.00-6.73 (m, 3H), 5.15 (dd, J = 11.2, 3.2 Hz, 1H), 3.35 (s, 3H), 3.23-2.95 (m, 2H); LC-MS (method I): Rt = 1.61 min, [M+NH4] + =400.2; HPLC (method A): purity 9.74%, Rt 6.5min; chiral HPLC (method H):>99.5%ee, Rt 1.35min.
[0538] The (4R)-enantiomer was obtained analogously.
[0539] 3-{[(4S)-5,5-Difluoro-4-hydroxy-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-1-yl]oxy}-5-fluorobenzonitrile (28a)
[0540]
[0541] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ=7.52-7.42 (m, 2H), 7.38 (m, 1H), 5.16 (m, 1H), 3.36 (s, 3H), 3.13 (m, 2H); LC-MS (method I): Rt=1.50 min, [MH]-=367.9; HPLC (method A): purity 99.1%, Rt 6.09 min; chiral HPLC (method A):>99.5% ee, Rt 2.87 min.
[0542] The (4R)-enantiomer was obtained analogously.
[0543] (4S)-5,5-Difluoro-1-(4-fluorophenoxy)-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol (29a)
[0544]
[0545] Prepare according to the general procedure; 1 H NMR (400 MHz, CD3OD): δ = 7.36-7.09 (m, 4H), 5.10 (dd, J = 11.3, 3.1 Hz, 1H), 3.30 (s, 3H), 3.19-2.87 (m, 2H); LC-MS (method B): Rt = 1.55 min, [M+NH4] + =382.2; HPLC (method A): purity 99.7%, Rt 6.29min; chiral HPLC (method C):>99.5%ee, Rt 1.53min.
[0546] The (4R)-enantiomer was obtained analogously.
[0547] (4S)-1-(3-Chloro-5-fluorophenoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol (30a)
[0548]
[0549] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 7.19-7.09 (m, 2H), 7.00 (m, 1H), 5.16 (m, 1H), 3.36 (s, 3H), 3.12 (m, 2H); LC-MS (method J): Rt = 2.71 min, [M+Na] + =420.8; HPLC (method A): purity 99.4%, Rt 7.26min; chiral HPLC (method I):>99.5%ee, Rt 2.31min.
[0550] The (4R)-enantiomer was obtained analogously.
[0551] 3-{[(4S)-5,5-Difluoro-4-hydroxy-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-1-yl]oxy}benzonitrile (31a)
[0552]
[0553] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 7.67-7.58 (m, 3H), 7.53 (m, 1H), 5.14 (dd, 1H), 3.14 (d, 3H), 3.12-3.00 (m, 2H); LC-MS (method E): Rt = 1.16 min, [M+H] +=371.9; HPLC (method A): purity 98.7%, Rt 5.90min; chiral HPLC (method J):>99.5%ee, Rt 1.35min.
[0554] The (4R)-enantiomer was obtained analogously.
[0555] (4S)-1-Ethoxy-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophene-4-ol (32a)
[0556]
[0557] Prepare according to the general procedure; 1 H NMR (300 MHz, CD3OD): δ = 5.05 (dd, J = 11.4, 2.7 Hz, 1H), 4.27-4.20 (m, 2H), 3.31 (s, 3H), 3.22-3.14 (m, 2H), 1.43 (t, J = 6.9 Hz, 3H), LC-MS (method L): Rt = 1.05 min, [M+H] + =299.00; HPLC (method B): purity 99.2%, Rt 4.15min; chiral HPLC (method L):>99.5%ee, Rt 1.30min.
[0558] The (4R)-enantiomer was obtained analogously.
[0559] (4S)-5,5-Difluoro-3-methylsulfonyl-1-(4,4,4-trifluorobutoxy)-4H,5H,6H-cyclopenta[c]thiophene-4-ol (33a)
[0560]
[0561] Prepare according to the general procedure; 1 H NMR (300 MHz, DMSO-d6): δ = 6.68 (d, J = 7.2 Hz, 1H), 4.97-4.95 (m, 1H), 4.26 (t, J = 6.3 Hz, 2H), 3.29-3.22 (m, 5H), 2.44-2.38 (m, 2H), 1.99-1.93 (m, 2H); LC-MS (method D): Rt = 2.63 min, [M+NH4] + =398.1; HPLC (method B): purity 99.5%, Rt 5.18 min; chiral HPLC (method K): >99.5% ee, Rt 2.31 min.
[0562] The (4R)-stereoisomer has been obtained analogously.
[0563] (4S)-1-(3,4-difluorophenoxy)-5,5-difluoro-3-methylsulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol (34a)
[0564]
[0565] Prepare according to the general procedure; 1 H NMR (300MHz, CDCl3): δ=7.23-7.17(m,1H),7.05-6.98(m,1H),6.93-6.87(m,1H),5.27-5 .21(m,1H),3.49(s,1H),3.26(s,3H),3.19-2.96(m,2H); LC-MS (Method E): Rt=1.24min,[M+H] + =404.85; HPLC (method A): purity 99.3%, Rt 6.44min.
[0566] The (4R)-stereoisomer has been obtained analogously.
[0567] The following compounds can be prepared in a similar manner:
[0568]
[0569]
[0570] The following examples are related to drugs.
[0571] Example A: Injection Vial
[0572] A solution of 100 g of the active ingredient of formula I and 5 g of disodium hydrogen phosphate in 3 L of double distilled water was adjusted to pH 6.5 using 2N hydrochloric acid, sterile filtered, transferred to injection vials, lyophilized under sterile conditions and sealed under sterile conditions. Each injection vial contained 5 mg of the active ingredient.
[0573] Example B: Suppository
[0574] A mixture of 20 g of the active ingredient of formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into molds and allowed to cool. Each suppository contains 20 mg of the active ingredient.
[0575] Example C: Solution A solution is prepared from 1 g of the active ingredient of formula I, 9.38 g NaH2PO4·2H2O, 28.48 g Na2HPO4·12H2O and 0.1 g benzalkonium chloride in 940 mL of double distilled water. The pH is adjusted to 6.8, and the solution is made up to 1 L and sterilized by irradiation. The solution can be used in the form of eye drops.
[0576] Example D: Ointment
[0577] 500 mg of the active ingredient of formula I are mixed with 99.5 g of vaseline under aseptic conditions.
[0578] Example E: Tablets
[0579] A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in a conventional manner to give tablets so that each tablet contains 10 mg of the active ingredient.
[0580] Example F: Dragees
[0581] Tablets are compressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
[0582] Example G: Capsules
[0583] 2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a customary manner so that each capsule contains 20 mg of active ingredient.
[0584] Example H: Ampoule
[0585] A solution of 1 kg of the active ingredient of Formula I in 60 L of double distilled water was sterile filtered, transferred into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contained 10 mg of the active ingredient.
Claims
1. Compounds of Formula I in R 1 Indicates A or [C(R 6 ) 2 ] q Cyc, R 2 Display SO 2 A, R 3 Indicates H or F, R 4 Indicates H or F, R 5 Represents H, R 6 Indicates H or A', A represents an unbranched or branched alkyl radical having 1 to 8 C atoms, wherein 1 to 5 H atoms may be replaced by OH, OA, F, Cl and / or Br and / or one or two non-adjacent CH 2 The groups may be replaced by O and / or NH groups, A' represents an unbranched or branched alkyl group having 1, 2, 3 or 4 C atoms, Cyc represents a cyclic alkyl radical having 3, 4, 5, 6 or 7 C atoms, of which 1 to 5 H atoms may be replaced by OH, OA, F and / or Cl, n represents 1 or 2, m represents 0, 1, 2 or 3, q represents 0, 1 or 2, or a pharmaceutically acceptable salt or stereoisomer thereof, including mixtures thereof in all ratios.
2. The compound according to claim 1, wherein R 1 represents A, or a pharmaceutically acceptable salt or stereoisomer thereof, including mixtures thereof in all ratios.
3. The compound according to claim 1 or 2, wherein A represents an unbranched or branched alkyl radical having 1 to 8 C atoms, wherein 1 to 5 H atoms may be replaced by OH and / or F and / or one or two non-adjacent CH 2 The groups may be replaced by O and / or NH groups, or a pharmaceutically acceptable salt or stereoisomer thereof, including mixtures thereof in all ratios.
4. The compound according to claim 1 or 2, wherein R 1 represents A, R 2 Display SO 2 A, R 3 Indicates H or F, R 4 Indicates H or F, R 5 Represents H, A represents an unbranched or branched alkyl radical having 1 to 8 C atoms, wherein 1 to 5 H atoms may be replaced by OH and / or F and / or one or two non-adjacent CH 2 The groups may be replaced by O and / or NH groups, n represents 1 or 2, m represents 0, 1, 2 or 3, or a pharmaceutically acceptable salt or stereoisomer thereof, including mixtures thereof in all ratios.
5. The compound according to claim 1, which is selected from the following: or a pharmaceutically acceptable salt or stereoisomer thereof, including mixtures thereof in all ratios.
6. A process for preparing a compound of formula I or a pharmaceutically acceptable salt and stereoisomer thereof according to any one of claims 1 to 5, Features a) reacting the compound of formula II with NaBH 4 reaction Where R 1 , R 2 , R 3 , R 4 , R 5 , n and m have the meanings as in claim 1, and / or The base or acid of formula I is converted into one of its salts.
7. A medicament comprising: at least one compound of formula I according to any one of claims 1 to 5 and / or pharmaceutically acceptable salts and stereoisomers thereof, including mixtures thereof in all ratios; and optionally a pharmaceutically acceptable carrier, excipient or vehicle.
8. Use of a compound of formula I according to any one of claims 1 to 5 or a pharmaceutically acceptable salt or stereoisomer thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and / or prevention of cancer and / or von Hippel-Lindau disease (VHL).
9. The use according to claim 8, wherein the medicament is used to treat and / or prevent a disease selected from the group consisting of cancers of the head, neck, eyes, mouth, throat, esophagus, bronchi, larynx, pharynx, chest, bones, lungs, colon, rectum, stomach, prostate, bladder, uterus, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidneys, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors, glioblastoma and renal cell carcinoma (RCC).
10. The use according to claim 8, wherein the medicament is for treating and / or preventing clear cell renal cell carcinoma (ccRCC).
11. A medicament comprising: at least one compound of the formula I according to any one of claims 1 to 5 and / or pharmaceutically acceptable salts and stereoisomers thereof, including mixtures thereof in all ratios; and at least one other pharmaceutically active ingredient.
12. Sets consisting of separate packages of: (a) an effective amount of a compound of formula I according to any one of claims 1 to 5 and / or its pharmaceutically acceptable salts and stereoisomers, including mixtures thereof in all ratios, and (b) an effective amount of other pharmaceutically active ingredients.
Citation Information
Patent Citations
Aryl ethers and uses thereof
WO2015035223A1
Aromatic compounds and uses thereof
WO2016144825A1
Substituted pyridines and uses thereof
WO2016144826A1
Compositions for use in treating pulmonary arterial hypertension
WO2016145032A1
Compositions for use in treating glioblastoma
WO2016145045A1
